TTY BIOPHARM COMPANY LIMITED

Year 2022 Annual General Meeting Minutes (Translation Version)

Time: May 26, 2022 (Thursday) 9:00 AM

Location: Building A, 2F., No. 19-10, Sanchong Rd., Nangang Dist., Taipei City, Taiwan

(International Convention Center of Nangang Software Park)

Total outstanding TTY shares: 248,649,959 shares

Total shares represented by shareholder present in person or by proxy: 186,312,928 shares

Percentage of shares held by shareholder present in person or by proxy: 74.92%

Director Present: Lin, Chuan; Chang, Wen-Hwa; Yang, Tze-Kaing; Chang, Hsiu-Chi; Liao, Ying-Ying; Hsueh, Ming-Ling (Independent Director & Chairman of the Audit

Committee); Lin, Tien-Fu (Independent Director)

Attendance: Hou, Ching-Lan, General Manager; Han, Yi-Lien, CPA of KPMG; Lin, Wen-Peng,

Lawyer of Giant Era International Law Office

Chairman: Lin, Chuan, Chairman

Recorder: Huang, Ching-Yi

Meeting procedures

I. Calling to the Meeting Order

The aggregate shareholding of the shareholder present in person or by proxy constituted a quorum. The Chairman called the meeting to order.

II. Chairman's Address (omitted)

III. Report Items

- 1. Year 2021 Business Report (See Attachment 1)
- 2. Audit Committee's Review Report on the year 2021 Financial Statements (See Attachment 2)
- 3. Report on Employee and Directors Remuneration in year 2021 (See Meeting Handbook)

IV. Ratification Items

Item One: (Proposed by the Board of Directors.)

Year 2021 Business Report and Financial Statements

Description:

- 1. The Company's year 2021 Business Report and Financial Statements have been approved by the Board of Directors and reviewed by Audit Committee.
- 2. The Company's year 2021 Financial Statements have been audited by KPMG Taiwan with "Unqualified Opinion"
- 3. Please refer to the Attachment 1 and Attachment 3 for year 2021 Business Report and

Financial Statements.

VOTING RESULTS: a total of 185,560,771 voting rights were represented by the presence of shareholders at the time of voting; therein 182,867,475 votes for (incl. 48,599,996 voting rights cast by electronic method), 23,738 votes against (incl. 23,738 voting rights cast by electronic method), 0 invalid votes and 2,669,558 votes abstention /no votes (incl. 1,627,869 voting rights cast by electronic method).

RESOLVED, 98.54% of total represented voting rights present voted for and this proposal was approved as proposed.

Item Two: (Proposed by the Board of Directors.)

Year 2021 Profit Distribution

Description:

- 1. Allocation of cash dividend proposed by the Board is total of NT\$ 745,949,877 or NT\$ 3.0 per share based on the number of shares recorded in the Register of Shareholders on the ex-dividend date. All cash dividends are rounded down to the dollar after discount any cents. The remaining amount will be treated as the other revenue of the Company. Upon the approval of the Annual Meeting of Shareholders, it is proposed that the Board of Directors shall be authorized to resolve the ex-dividend date, payment date and other relevant issues.
- 2. Please refer to the Attachment 4 for year 2021 Profits Distribution Table.

VOTING RESULTS: a total of 185,560,771 voting rights were represented by the presence of shareholders at the time of voting; therein 182,864,274 votes for (incl. 48,596,795 voting rights cast by electronic method), 27,938 votes against (incl. 27,938 voting rights cast by electronic method), 0 invalid votes and 2,668,559 votes abstention /no votes (incl. 1,626,870 voting rights cast by electronic method).

RESOLVED, 98.54% of total represented voting rights present voted for and this proposal was approved as proposed.

V. Discussion Items

Item One: (Proposed by the Board of Directors.)

The Amendment of "Articles of Incorporation"

Description:

- 1. The "Articles of Incorporation" is proposed to be amended in accordance with the amendment of applicable laws and actual operational needs.
- 2. Please refer to the Attachment 5 for Amendment Comparison Table of "Articles of Incorporation".

VOTING RESULTS: a total of 185,560,771 voting rights were represented by the presence of shareholders at the time of voting; therein 168,436,540 votes for (incl. 34,169,061 voting rights cast by electronic method), 13,607,236 votes against (incl. 13,607,236 voting rights cast by electronic method), 0 invalid votes and 3,516,995 votes abstention /no votes (incl. 2,475,306 voting rights cast by electronic method).

RESOLVED, 90.77% of total represented voting rights present voted for and this proposal was approved as proposed.

Item Two:

(Proposed by the Board of Directors.)

The Amendment of "Procedures for Acquisition or Disposal of Assets"

Description:

- 1. The "Procedures for Acquisition or Disposal of Assets" is proposed to be amended in accordance with the amendment of "Regulations Governing the Acquisition and Disposal of Assets by Public Companies" released by Financial Supervisory Commission on January 28, 2022 with issue number of 1110380465.
- 2. Please refer to the Attachment 6 for Amendment Comparison Table of "Procedures for Acquisition or Disposal of Assets".

VOTING RESULTS: a total of 185,560,771 voting rights were represented by the presence of shareholders at the time of voting; therein 182,036,964 votes for (incl. 47,769,485 voting rights cast by electronic method), 20,812 votes against (incl. 20,812 voting rights cast by electronic method), 0 invalid votes and 3,502,995 votes abstention /no votes (incl. 2,461,306 voting rights cast by electronic method).

RESOLVED, 98.10% of total represented voting rights present voted for and this proposal was approved as proposed.

VI. Extraordinary Motions: None.

VII. Adjournment: The Chairman announced the meeting adjourned at 9:15 am on May 26, 2022.

TTY BIOPHARM COMPANY LIMITED

Business Report

I. The Company's Business Result for year 2021

(1) Business Plan Implementation Result

The Company's consolidated net business revenue for year 2021 reached NT\$4,535,610 thousands, which represents an increase by NT\$313,774 thousands (7.43%) compared to that of NT \$4,221,836 thousands for year 2020. The increase was mainly caused by the increasing volume of influenza vaccines and manufacturing of COVID-19 vaccines for Medigen Vaccine Biologics Corp. Net profit attributed to the parent company for year 2021 totaled NT\$831,894 thousands which represented a decline by NT\$92,284 thousands (-9.99%) compared to that of NT\$924,178 thousands in year 2020. The decrease was mainly caused by the recognition of penalty of NT 220,000 thousands from Fair Trade Commission. The Company has filed an administrative relief to revoke of this administrative penalty with acceptance by the Court.

(2) Budget Implementation Status

The Company's net business revenue for year 2021 is NT\$ 4,038,636 thousands, Pre-tax net profit is NT\$ 1,082,219 thousands, achieving 99.92% of the annual budget target.

(3) Income & Expenditure and Profitability Analysis

Item	Year	2021	2020
Income &	Interest Income (in thousands)	442	1,126
Expenditure	Interest Expenditure (in thousands)	17,288	17,358
	Return on Assets %	9.91	10.95
Profitability	Return on Equity %	15.67	16.77
Analysis	Net Profit Margin %	20.60	24.84
	Earnings Per Share (NTD)	3.35	3.72

(4) Research & Development Status

TTY Biopharm has accumulated professional capabilities in the development and manufacture of drugs and provides comprehensive solutions in the field of drug delivery systems. Dosage development includes development of formulations, analysis methodology and processes, animal testing, functional formulation, GMP manufacturing, and CMC preparation. We are firmly committed

to our core philosophy to benefit more patients and maximizing shareholder value.

The Company is actively engaged in the research and development of long-acting microsphere products for the treatment of Acromegaly and functional gastric, intestinal, and pancreatic endocrine tumors. Besides, overseas markets for two liposome products are developed in cooperation with leading international companies. The Company also actively implements relevant procedures for the other products to accelerate access to overseas markets.

Looking forward, the Company shall continue to utilize innovation as its core value, develop strategies based on broad and enhanced technology platform and think strategically to maintain the Company's competitiveness leading position for the purpose of maximizing respective stakeholders' values.

II. Overview of the year 2022 Business Plan

(1) Operation Policy

Ever since its incorporation, TTY has experienced several critical strategic leaps and successfully transformed itself into a "specialty drug and new drug development oriented innovative international biopharma company" for the purpose of creating excellence and ever-lasting business. In addition to the in-depth exploration of Taiwan market and major countries in Asia in order to obtain stable growth for domestic and offshore businesses, we also proceed to expand primary markets and emerging markets across the world. TTY explores its self-developed product revenue and brand efficiency through direct sales or collaboration with strategic partners. TTY is also closely connected with international expert social media groups and provides treatment solutions with the best drug economic values. TTY is dedicated to become an international biopharma company specialized in developing special formulation and biotechnological drugs, marketing and manufacturing. Additionally, TTY Biopharm also emphasizes its performance of corporate social responsibility and shall endeavor its efforts on environment, society and corporate governance to fulfill its sustainability responsibility.

(2) Quantity and Basis for Projected Sales

In year 2022, the Company expects to sell 333,100 thousands tablets of oral products and 6,250 thousands vials of injection. The Company's projected sales volume has been established in accordance with IQVIA statistic report and under considerations of possible changes in market supply and demand going forward, new product development speed as well as national health insurance policy.

(3) Critical Production and Marketing Policies

For the upcoming year, TTY shall continue its strategy and goal from the past, and shall utilize its previous achievements as a basis during its relentless dedication to self-challenge while approaching toward its next milestone:

With respect to "marketing strategy," we shall continue to evaluate major countries in Asia, global primary markets, and emerging markets in addition to our in-depth exploration of Taiwan market. Exploration of TTY product revenue and brand efficiency will be conducted through management of direct sales and strategic partner collaboration. As for "Research & Development

Strategy," we shall continue to enhance the development of specialty pharma platform. In the meantime, we shall balance our needs for short/medium/long term R&D and be engaged in aggressive and cautious search for and assessment of licensing-in and development targets in a bid to enhance product assortments for respective business divisions in the Company. With respect to "Production Strategy," we shall continue to establish and maintain drug manufacturing bases meeting international quality requirements, purchase manufacturing equipment, and enhance production capacity planning which comes with flexibility and economies of scale for the purpose of ensuring our cost and competitive advantages.

III. The Company's Future Development Strategy

Corporate Vision: "Enhance Human Life Quality with Technology"

Corporate Mission: "Commitment to development and manufacturing of specialty pharma (patentable or high entry barrier), biological products, new medical technology and new drugs; Enhancement of TTY product assortments; Continuous enhancement of high market-entrance obstacle drug development platform as well as undisrupted extension of utilization efficiency over such platform," "Specialized in the in-depth exploration and international development over manufacturing and R&D for anti-cancer, critical illness anti-infection and specialty pharma," "Becoming one of the most innovative biopharma company in the world as well as the best collaborating partner for international biotechnology company in drug development and international market promotion."

For future development, TTY shall, in addition to obtaining drugs approval to maximize efficiency on current R&D achievements, continue to explore international markets and aggressively look for international collaboration opportunities, and achieve its development goals through the following critical strategies:

- (1) Balanced evaluations and investment over early/middle/final phase drug development targets for the purpose of enhancing product assortments and competency (specialty pharma, biopharma, new drug) and sustaining this organization's short/long term growth momentum and integration of value chain;
- (2) Collaboration with international cooperation partners in order to speed up development for specialty pharma and new drugs which come with unmet medical needs, high entry barrier (technology, manufacturing) and high drug economic values;
- (3) Development of specialty pharma through competitive in-house and joint developments and concentration in an ongoing basis on the implementation of "localized" business activities and life cycle management "best suited for local community" in respective target markets;
- (4) Establishment, renewal and maintenance of drug manufacturing bases which comply with international quality standards and requirements for the purpose of creating stable operation patterns for Contract Development and Manufacturing Organization (CDMO) and adding values to TTY international business development;
- (5) Enhance production capacity and supply chain management and complete optimal integration and management encompassing from R&D to production through critical strategic events of M&As, strategic alliance and joint venture.

(6) Continued implementation of production process improvement and enhancement of production capacity planning (capable of supplying international mass production demand) which comes with flexibility and economies of scale for the purpose of ensuring cost advantage and competency;

(7) Rapid acquisition and cultivation of local talents with "entrepreneurial spirit" and continued enhancement over product development, operation, and marketing talents possessing balanced developments in the fields of "science, regulation, business management;"

(8) Accelerate expansion of overseas business footprints, enhance agency sales target management over existing collaborating partners and continue to establish powerful and preeminent overseas self-operated teams for the purpose of generating the Company's mid-and-long term revenue growth potential and diversified development for internationalization.

IV. Impacts from External Competition Environment, Regulatory Environment and Macro-Economic Environment

Under the policy of stricter controlling drug expenditure conducted by governments and the impact of regional industrial competition, China, India, and emerging countries have successively stepped into generic drug industry, which has led to a status of cut-throat price war. In addition, Taiwanese drug manufacturers lack economies of scale, coupled with challenging export sales resulted from increasing documents requirement with certain regulatory obstacles, has caused excessive domestic competition and staggers development of the drug market in Taiwan.

In addition, production costs have been constantly rising upon implementation of PIC/S in the wake of the enactment of increasingly strict manufacturing laws and regulations. Besides that, price negotiation from hospital and that for drugs covered by National Health Insurance have been adjusted numerous times, which has led to an imbalance between input and output and a further squeeze on revenues and profits of drug manufacturers.

2021 operation environment was full of challenges due to COVID-19 pandemic. Geopolitical instability and US-China trade war caused impact to global economy. Looking into the year of 2022, trend for global economy has not exposed a silver lining. Economic growth for major countries is struggling, testing again corporate's capability to respond to contingency and effectiveness in cost control. TTY Biopharm shall continue to exploit and develop suitable drugs, explore channels, acquire drugs approval or obtain applications of new drugs to boost revenue growth and expand corporate territory. At the meantime, the Company shall exert aggressive control over expenses for the purpose of maximizing shareholder's equities.

Chairman of the Board: Lin, Chuan

Responsible Management: Lin, Chuan

Responsible Accountant: Wang, Shu-Wen

TTY BIOPHARM COMPANY LIMITED

Audit Committee's Review Report on the year 2021 Financial Statements

The Board of Directors presented the year 2021 Business Report, Financial Statement (including the consolidated financial statement) and profit distribution proposal. The Financial Statement (including the consolidated financial statement) was audited by KPMG Taiwan and the results were compiled into a report. The aforementioned reports and statements were audited and found satisfactory by the Company's audit committee. They are hereby submitted respectfully for examination pursuant to the regulations set forth in Article 14-4 of the Securities and Exchange Act and Article 219 of the Company Act.

Submitted to: Year 2022 Annual General Meeting of Shareholders of the Company

Hsueh, Ming-Ling Chairman of the Audit Committee March 9, 2022



安侯建業群合會計師事務的 KPMG

台北市110615信義路5段7號68樓(台北101大樓) 68F., TAIPEI 101 TOWER, No. 7, Sec. 5, Xinyi Road, Taipei City 110615, Taiwan (R.O.C.) 電 話 Tel 傳 真 Fax + 886 2 8101 6666 + 886 2 8101 6667

址 Web home.kpmg/tw

Independent Auditors' Report

To the Board of Directors TTY Biopharm Company Limited:

Opinion

We have audited the accompanying financial statements of TTY Biopharm Company Limited ("the Company"), which comprise the balance sheets as of December 31, 2021 and 2020, the statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, based on our audits and the report of another auditor (please refer to the Other Matter paragraph), the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and its financial performance and its cash flows for the years then ended in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers".

Basis for Opinion

We conducted our audits in accordance with the Regulations Governing Auditing and Certification of Financial Statements by Certified Public Accountants and the auditing standards generally accepted in the Republic of China. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Certified Public Accountants Code of Professional Ethics in Republic of China (the "Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. Based on our audits and the report of another auditor, we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.

Other Matter

We did not audit the financial statements of PharmaEngine, Inc. Those statements were audited by another auditor, whose report have been furnished to us, and our opinion, insofar as it relates to the amounts included for certain equity-accounted investees, are based solely on the report of another auditor. The amount of long-term investment in the investee company represented 10.27% and 10.25% of the related total assets as of December 31, 2021 and 2020, respectively, and the related investment gains represented 7.05% and 9.51% of the profit before tax for the years ended December 31, 2021 and 2020, respectively.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Key audit matters for the financial statements are stated as follows:



1. Occurrence of revenue from selling pharmaceuticals and chemical drugs

Please refer to Notes 4(p) of the financial statements for the accounting principles on revenue recognition. Revenues are recognized by net values of contract prices, less sales returns and allowances, after controls of the products are transferred to the customers.

Key audit matters:

The Company's sales is mainly from the selling of pharmaceuticals and chemical drugs. Because the customers are diversity and numerous, it takes longer time to verify sales transactions. Therefore, the occurrence in sales transactions is one of the important issue in performing our audit procedures.

Auditing procedures performed:

- Testing the effectiveness of the design and implementing the internal control system of sales and collection operation;
- Testing the samples of sales transaction before and after the balance sheet date to ensure the correctness of sales revenue;
- Inspecting the related documents to ensure the adequacy and reasonableness of revenue recognition.

2. Inventory valuation

Please refer to Notes 4(g), and 5 of the financial statements for the accounting principles on the inventory valuation, significant accounting assumptions and judgments, and major sources of estimation uncertainty.

Key audit matters:

The Company's primary operating items are manufacturing and processing various kinds of pharmaceuticals. The pharmaceutical industry in Taiwan is susceptible to the constant amendments of its law, resulting in large price fluctuation of pharmaceutical products, which will affect the carrying value of inventories to exceed its net value. Because of these uncertainties, the Company's revenue and income may be effected by the price fluctuations. If the assessment of the net realizable value of the inventory is not appropriate, it will lead to a material misstatement of the financial statements.

Auditing procedures performed:

- Overviewing the stock ageing list, analyzing the movement of stock ageing by period;
- · Obtaining the certificate documents to verify the correctness of the stock's expiry date; and
- Sampling the replacement cost and market price of inventories, and recalculating the net realizable value by marketing expense rate, to ensure the reasonableness of net realizable value adopted by the Company.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.



Those charged with governance (including the Audit Committee) are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the auditing standards generally accepted in the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with auditing standards generally accepted in the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- 1. Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- 2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- 3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- 4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- 5. Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- 6. Obtain sufficient and appropriate audit evidence regarding the financial information of the investment in other entities accounted for using the equity method to express an opinion on this financial statements. We are responsible for the direction, supervision and performance of the audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audit resulting in this independent auditors' report are Yilien Han and Shu-Ying Chang.

KPMG

Taipei, Taiwan (Republic of China) March 9, 2022

Notes to Readers

The accompanying financial statements are intended only to present the financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such financial statements are those generally accepted and applied in the Republic of China.

The independent auditor's audit report and the accompanying financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditor's audit report and financial statements, the Chinese version shall prevail.

(English Translation of Financial Statements Originally Issued in Chinese)

TTY BIOPHARM COMPANY LIMITED

Balance Sheets

December 31, 2021 and 2020

(Expressed in Thousands of New Taiwan Dollar)

		December 31,		December 31, 2				December 31, 20		December 31, 20	20_
	Assets	Amount		Amount	<u>%</u>		Liabilities and Equity	Amount	<u>%</u> _	Amount	<u>%</u>
1100	Current assets:	\$ 261.30	. 2	104 501	3	2100	Current liabilities:	\$ 1,650,000	10	1,650,000	10
1100	Cash and cash equivalents (note 6(a) and (q))	- ,		194,591	-	2100	Short-term borrowings (note 6(h) and (q))	, , , , , , , , , , , , , , , , , , , ,	19	,,	
1150	Notes receivable, net (note 6(b) and (q)	18,53		17,652	-	2130	Contract liabilities-current(note 6(n))	40,099	-	,	-
1170	Accounts receivable, net (note 6(b) and (q)	868,64		778,724	9	2150	Notes payable (note 6(q))	56,794	1	1,922	-
1180	Accounts receivable due from related parties, net (note 6(b), (q)and 7)	142,85		86,155	1	2170	Accounts payable (note 6(q))	115,777	1	,	2
1200	Other receivables, net (note 6(q) and 7)	20,13		91,464	1	2230	Current tax liabilities	143,290	2	94,049	1
130X	Inventories (note 6(c))	868,84		1,016,308	12	2200	Other payables (note 6(o) and (q))	442,289	5	414,126	5
1410	Prepayments	23,20	3 -	24,139	-	2300	Other current liabilities	19,523	-	20,256	-
1470	Other current assets (note 6(g))	8	<u> </u>	4,465		2320	Long-term liabilities, current portion (note 6(i) and (q))	400,000	5		
		2,203,59	27	2,213,498	26			2,867,772	33	2,346,496	27
	Non-current assets:						Non-Current liabilities:				
1550	Investments accounted for using equity method, net (note 6(d))	3,352,24	39	3,403,670	40	2540	Long-term borrowings (note 6(i) and (q))	-	-	400,000	5
1600	Property, plant and equipment (note 6(e))	2,485,52) 29	2,558,085	30	2570	Deferred tax liabilities (note 6(k))	260,519	3	271,826	3
1760	Investment property, net (note (f))	113,39	5 1	114,163	1	2640	Net defined benefit liability, non-current (note 6(j))	52,597	1	45,500	1
1780	Intangible assets	39,78	l -	34,591	-	2645	Guarantee deposits received (note 6(q) and 7)	3,637	-	3,559	-
1840	Deferred tax assets (note 6(k))	45,00	5 1	43,940	1	2650	Credit balance of investments accounted for using equity method (note 6(d))	1,300	-	/	-
1915	Prepayments for business facilities	6,89	4 -	4,975	-	2670	Other non-current liabilities (note 6(q))	152,792	2	2,268	
1920	Refundable deposits paid (note 6(q))	29,36	5 -	19,696	-			470,845	6	758,485	9
1984	Other non-current financial assets (note 6(g), (q) and 8)	151,000	3 2	151,193	2		Total liabilities	3,338,617	39	3,104,981	36
1990	Other non-current assets (note 6(g))	79,67	<u>1</u>	10,936			Equity (note 6(1)):				
		6,302,87	7 73	6,341,249	74	3100	Capital stock	2,486,500	29	2,486,500	29
						3200	Capital surplus (note 6(d))	311,876	4	337,997	4
						3310	Legal reserve	1,198,617	14	1,093,808	13
						3320	Special reserve	133,709	2	110,154	2
						3350	Unappropriated retained earnings	1,235,223	14	1,555,016	18
						3400	Other equity interest	(198,070)	(2)	(133,709)	(2)
							Total equity	5,167,855	61	5,449,766	64
	Total assets	\$8,506,47	100	8,554,747	100		Total liabilities and equity	\$ <u>8,506,472</u>	100	8,554,747	<u>100</u>

(English Translation of Financial Statements Originally Issued in Chinese) TTY BIOPHARM COMPANY LIMITED

Statements of Comprehensive Income

For the years ended December 31, 2021 and 2020

(Expressed in Thousands of New Taiwan Dollar, Except for Earnings Per Share)

		2021		2020	
		Amount	%	Amount	%
4000	Operating revenue (note 6(n) and 7)	\$ 4,038,636	100	3,721,161	100
5000	Operating costs (note 6(c), (j) and 12)	1,613,866	40	1,508,605	41
	Gross profit	2,424,770	60	2,212,556	59
5910	Less:Unrealized profit (loss) from sales	18,474	-	23,316	1
5920	Add:Realized profit (loss) from sales	23,316	-	21,870	1
	Gross profit, net	2,429,612	60	2,211,110	59
6000	Operating expenses (note 6(j) and 12):				
6100	Selling expenses	736,328	18	799,945	21
6200	Administrative expenses (note 6(o))	301,965	8	287,363	7
6300	Research and development expenses	245,778	6	216,594	6
6450	Expected credit losses (note 6(b))	12,024	_	-	_
		1,296,095	32	1,303,902	34
	Net operating income	1,133,517	28	907,208	25
	Non-operating income and losses (note 6(p) and 7):	1,100,017			
7100	Interest income	442	_	1,126	_
7010	Other income	16,930	_	16,818	1
7020	Other gains and losses, net	(170,936)	(4)	17,842	1
7050	Finance costs, net	(17,288)	- (1)	(17,358)	(1)
7070	Share of profit of subsidiaries and associates accounted for using equity	119,554	3	203,819	5
7070	method, net (note 6(d))	117,334		203,617	
	method, het (hote o(d))	(51,298)	(1)	222,247	6
	Profit before tax	1,082,219	27	1,129,455	31
7950	Less: Income tax expenses (Note 6(k))			205,277	
7930		250,325	$\frac{-6}{21}$	924,178	$\frac{-6}{25}$
8300	Profit for the period	831,894		924,176	
8310	Other comprehensive income: Components of other comprehensive income (loss) that will not be				
0310	reclassified to profit or loss				
8311	(Losses) gains on remeasurements of defined benefit plans (note 6(j))	(10,809)		7,920	
8316	Unrealized gains from investments in equity instruments measured at fair	(10,009)	-	15,132	-
0310	value through other comprehensive income	-	-	13,132	-
8330	Share of other comprehensive loss of subsidiaries, associates and joint	(5,802)		(7,097)	
0330	ventures accounted for using equity method, components of other	(3,802)	-	(7,097)	-
	comprehensive income that will not be reclassified to profit or loss				
9240					
8349	Income tax related to components of other comprehensive (loss) income that		<u> </u>		
	will not be reclassified to profit or loss	(1((11)		15.055	
	Components of other comprehensive (loss) income that will not be	(16,611)		15,955	
9260	reclassified to profit or loss				
8360	Components of other comprehensive income (loss) that will be reclassified				
0271	to profit or loss	(97.520)	(2)	(92 (25)	(2)
8361	Exchange differences on translation	(87,520)	(2)	(82,635)	(2)
8380	Share of other comprehensive (loss) income of subsidiaries, associates and	(182)	-	268	-
	joint ventures accounted for using equity method, components of other				
0200	comprehensive income that will be reclassified to profit or loss	17.540		16 400	(1)
8399	Income tax related to components of other comprehensive loss that may be	17,540		16,480	<u>(1</u>)
	reclassified to profit or loss	(70.1(0)	(2)	((5,007)	(1)
	Components of other comprehensive loss that may be reclassified to	(70,162)	(2)	(65,887)	<u>(1</u>)
0200	profit or loss	(0.6.772)	(2)	(40.022)	(1)
8300	Other comprehensive loss for the period, net of tax	(86,773)	(2)	(49,932)	(1)
	Total comprehensive income for the period	\$ <u>745,121</u>	19	874,246	24
	Earnings per share, net of tax (note 6(m))	0	2.25		2.52
	Basic earnings per share	\$	3.35		3.72
	Diluted earnings per share	\$	3.34		3.71
		·			

See accompanying notes to financial statements.

(English Translation of Financial Statements Originally Issued in Chinese) TTY BIOPHARM COMPANY LIMITED

Statements of Changes in Equity

For the years ended December 31, 2021 and 2020

(Expressed in Thousands of New Taiwan Dollar)

	Share capital	-	R	etained earning	gs		Unrealized gains (losses) on financial assets measured at fair	rest	
						differences on	value through		
	- 41				Unappropriated	translation of	other		
	Ordinary shares	Capital surplus l	Legal reserve	Special reserve	retained earnings	foreign financial statements	comprehensive income	Total other equity interest	Total equity
Balance on January 1, 2020	\$ 2,486,500	338,514	1,003,556	110,154	1,591,777	(80,724)		40,135	5,570,636
Net income		-	-	_	924,178	-			924,178
Other comprehensive income	-	-	-	-	7,920	(65,887)	8,035	(57,852)	(49,932)
Total comprehensive income	-	-	-	-	932,098	(65,887)	8,035	(57,852)	874,246
Appropriation and distribution of retained earnings:									
Legal reserve appropriated	-	-	90,252	-	(90,252)) -	-	-	-
Cash dividends of ordinary share	-	-	-	-	(994,599)) -	-	-	(994,599)
Other changes in capital surplus:									
Changes in equity of investments accounted for using equity method	-	(517)	-	-	-	-	-	-	(517)
Disposal of investments in equity instruments measured at fair value through other comprehensive income		-			115,992		(115,992)	(115,992)	
Balance on December 31, 2020	2,486,500	337,997	1,093,808	110,154	1,555,016	(146,611)	12,902	(133,709)	5,449,766
Net income	-	-	-	-	831,894	-	-	-	831,894
Other comprehensive income					(10,809)	(70,162)	(5,802)	(75,964)	(86,773)
Total comprehensive income		-			821,085	(70,162)	(5,802)	(75,964)	745,121
Appropriation and distribution of retained earnings:									
Legal reserve appropriated	-	-	104,809	-	(104,809)) -	-	-	-
Special reserve appropriated	-	-	-	23,555	(23,555)	-	-	-	-
Cash dividends of ordinary share	-	-	-	-	(994,600)	-	-	-	(994,600)
Other changes in capital surplus:									
Changes in equity of investments accounted for using equity method	-	(13,893)	-	-	-	-	-	-	(13,893)
Other changes in capital surplus	-	710	-	-	-	-	-	-	710
Difference between consideration value and carrying amount of subsidiaries acquired or disposed	-	(13,155)	-	-	(6,311)	-	-	-	(19,466)
Changes in ownership interests in subsidiaries	-	217	-	-	-	-	-	-	217
Disposal of investments in equity instruments measured at fair value through other comprehensive income		-	<u>-</u>		(11,603)		11,603	11,603	
Balance on December 31, 2021	\$ 2,486,500	311,876	1,198,617	133,709	1,235,223	(216,773)	18,703	(198,070)	5,167,855

See accompanying notes to financial statements.

(English Translation of Financial Statements Originally Issued in Chinese) TTY BIOPHARM COMPANY LIMITED

Statements of Cash Flows

For the years ended December 31, 2021 and 2020 (Expressed in Thousands of New Taiwan Dollar)

Profit before tax \$ 1,082,219 1,129,455 Adjustments to reconcile profit (loss): Second 1 1,20,265 Depreciation expense 1 40,926 1 32,489 Amoritzation expense 7,657 5,226 Expected credit losses 12,024 − Interest expense 1 7,288 17,388 Interest income (42) (1,105) Closses on disposal of property, plant and equipment 108 3,21 Unscalinged profit from sales (33,16) (21,83) Realized profit from sales (33,16) (21,82) Changes in operating assets and liabilities (39,75) (51,82) Notes receivable (88 (1,130) 3,462 Other crecivable (13,30) 3,462 1,130 Other crecivable (31,16) (31,11) (19,160) Other courtent assets (31,16)			2021	2020	
Adjistments to reconcile profit (loss): Depreciation expense	Cash flows from (used in) operating activities:	¢	1 002 210	1 120 455	
Depreciation expense		Ф	1,062,219	1,129,433	
Depectation expense 140,926 132,489 Amontrization expense 7,655 5,226 Expected credit losses 12,024 Fixpected credit losses 17,288 17,358 Interest income 7,488 17,358 Interest income 7,489 17,358 Interest income 140,210 140,220 141,250 Share of profit of investments accounted for using the equity method 140,250 140,250 Losses on disposal of property, plant and equipment 108 22,110 Urneralized profit from sales 18,474 22,316 Realized profit from sales 18,474 23,316 Realized profit from sales 13,310 20,177 Realized profit from sales 13,310 20,177 Realized profit from sales 13,310 20,177 Total adjustments to recornicile profit (loss) 39,759 (51,029) Changes in operating assets and liabilities: 39,750 (51,029) Changes in operating assets and liabilities: 13,30 30,462 Inventories 147,463 21,304 Other receivable 1,330 30,462 Inventories 147,463 21,304 Inventori					
Amortization expense			140,926	132,489	
Expected credit loses					
Interest income			12,024	-	
Share of profit of investments accounted for using the equity method 108 32 Unrealized profit from sales 18,474 23,316 Realized profit from sales 18,474 23,316 Gain from lease modification (233) (7) Amortization of deferred profit (13,183) (2,917) Total adjustments to reconcile profit (loss) 30,750 (31,29) Total adjustments to reconcile profit (loss) (878) (1,653) Accounts receivable (878) (1,653) Accounts receivable (878) (1,653) Accounts receivable (13,30) (30,40c) Other receivable (13,30) (30,40c) Inventories (13,40) (13,40) (19,400) Other current assets (13,40) (19,400) Other current assets (13,40) (19,400) Current contract liabilities (24,604) (3,487) (22,617) Accounts payable (34,871) (22,617) (22,617) Other payable (34,871) (22,617) (22,617) Other payable (34,871) (22,617) (22,617) Other payable (34,871) (22,617) (22,689) Total changes in operating assets and liabilities (2,208) (4,675) (22,689) Total changes in operating liabilities (2,208) (3,4675) (2,289) (3,4675)	Interest expense		17,288	17,358	
Losses on disposal of property, plant and equipment 18,874 23,316 Realized profit from sales 12,316 (21,323)			(442)	(1,126)	
Unrealized profit from sales 18,474 23,316 Cal,870 Gain from lease modification (232) (7,70 Cal) (232) (2,70 Cal) (2,70			(, ,	. , ,	
Realized profit from sales (2,31) (2,18) Gain from lases modification (2,32) (7) Amortization of deferred profit (loss) 39,750 (5)(10,29) Changes in operating assets and liabilities: (878) (1,63) Notes receivable (158,641) 7,008 Other receivable (158,641) 7,008 Other crocivable 147,463 (29,403) Other crocivable (5,411) (91,603) Other crocivable (5,411) (19,100) Other crocivable (5,411) (19,100) Other crocivable (5,411) (19,100) Other crocivation (5,411) (19,100) Current contract liabilities (5,411) (19,100) Other payable (3,87) (5,22) Other payable (3,124) (6,102) Other payable (3,124) (6,102) Total changes in operating liabilities (2,12) (2,809) Total changes in operating assets and liabilities (2,132) (2,809) Total changes in operating assets and liab					
Gain from lease modification (31,83) (2,917) Total adjustments to reconcile profit (loss) 39,750 (51,029) Changes in operating assets and liabilities: (18,864) 7,008 Notes receivable (18,864) 7,008 Other receivable 13,30 30,462 Inventories 147,463 (29,403) Other current assets 5,315 (8,014) Other current sontract liabilities 24,604 3,318 Notes payable 44,604 3,318 Accounts payable 64,871 (22,617) Other current liabilities 2,208 (4,675) Net defined benefit liability 2,208 (4,675) Other current liabilities 2,13,728 86,843 Total changes in operating assets and liabilities 2,13,728 86,843 Total changes in operating assets and liabilities 2,13,728 86,843 Total changes in operating assets and liabilities 2,13,728 86,843 Total changes in operating assets and liabilities 2,13,728 86,843 Total changes in operating assets and liabi					
Amotization of deferred profit (Ioss) 39,750 5(10,200)				` ' '	
Total adjustments to reconcile profit (loss) 39,750 (51,029) Changes in operating assets and liabilities: (1,63) (1,63) Accounts receivable (1330) 30,462 Other receivable 1,300 30,462 Other receivable 1,340 30,462 Inventories 1,443 30,462 Inventories 1,511 (191,600) Other current assets 5,515 (80,141) Other current abilities 24,604 3,318 Notes payable 198,672 1,202 Accounts payable 31,243 (10,23) Other current liabilities 2,133 (10,23) Other payable 31,243 (10,23) Other current liabilities 2,132 (2,689) Total changes in operating liabilities 31,233 (4,672) Total changes in operating assets and liabilities 213,728 (8,648) Total changes in operating assets and liabilities 213,728 (8,648) Total changes in operating assets and liabilities 213,728 (8,648) To					
Notes receivable					
Notes receivable (878) (1,630) Accounts receivable (158,641) 7,008 Other receivable 1,330 30,462 Inventories 147,463 (219,403) Other current assets 5,315 (8,014) Total changes in operating assets 5,311 (191,600) Current contract liabilities 24,604 3,318 Notes payable 198,672 1,202 Accounts payable (34,871) (22,617) Other querent liabilities (2,208) (4,675) Net defined benefit liability (2,208) (4,675) Net defined benefit liabilities 23,372 (86,484) Total changes in operating assets and liabilities 233,728 (86,484) Total changes in operating assets and liabilities 233,728 (86,484) Interest received 42 (1,20,20) (1,20,20) Interest received 112,197 59,964 (1,20,20) (1,20,20) (1,20,20) (1,20,20) (1,20,20) (1,20,20) (1,20,20) (2,20,20) (2,20,20) (39,730	(31,029)	
Accounts receivable			(878)	(1.653)	
Other receivable 1,330 30,462 Inventories 147,463 (219,403) Other current assets 5,315 (8,014) Total changes in operating assets (5,411) (191,600) Current contract liabilities 24,604 3,318 Notes payable (34,871) (22,617) Other payable (34,871) (22,617) Other current liabilities (2,208) (4,675) Net defined benefit liability (2,088) (4,675) Net defined benefit liabilities 23,372 (2,889) Total changes in operating assets and liabilities 23,372 (2,889) Total adjustments 28,806 (329,113) Cash inlows penerated from operations 1,330,286 800,342 Interest received 112,197 59,466 Increase paid (16,772) (17,495) Increase paid (16,772) (17,495) Net cash flows from (used in) investing activities 2 (17,95) Cash flows from (used in) investing activities 1 (36,552) (155,962) <td></td> <td></td> <td></td> <td></td>					
Inventories			. , ,		
Other current assets 5.315 (8.014) Total changes in operating assets 5.411 (191,600) Current contract liabilities 24,604 3.318 Notes payable 198,672 1,202 Other payable 31,243 (61,023) Other current liabilities 2,208 (4,675) Net defined benefit liabilities 213,728 (86,844) Total changes in operating liabilities 213,728 (86,844) Total changes in operating assets and liabilities 208,317 (27,808) Total adjustments 248,967 (329,13) Cash inflow generated from operations 1,330,286 800,342 Interest received 12,126 (10,722) (17,405) Income taxes paid (16,772) (17,405) (17,405) Income taxes paid (15,00) (17,722) (30,910) Net cash flows from operating activities 2 (25,00) (27,722) Cash flows from (used in) investing activities 1 (30,722) (25,602) (71,722) Cash flows from (used in) investing activitie					
Total changes in operating assets (5.411) (191,600) Current contract liabilities 24,604 3.318 Notes payable (34,871) (22,617) Other payable (31,243) (61,023) Other current liabilities (2,208) (4,675) Net defined benefit liability (3,712) (2,689) Total changes in operating liabilities 213,728 (86,849) Total changes in operating assets and liabilities 208,317 (278,894) Total changes in operating assets and liabilities 208,317 (278,894) Total changes in operating assets and liabilities 213,728 80,342 Interest received 442 (12,76) Interest received 412 (12,76) Interest received (195,916) (30,1910) Net cash flows from operating activities (195,916) (30,1910) Net cash flows from (used in investing activities (195,916) (30,1910) Net cash flows from operating activities (195,916) (31,516) Poceeds from disposal of financial assets at fair value through other comprehensive income (56				(8,014)	
Current contract liabilities 24,604 3,318 Notes payable 198,672 1,202 Accounts payable 31,243 (61,023) Other payable 31,243 (61,023) Other current liabilities 2,208 4,675 Net defined benefit liability 2,208 (3,712) 2,6889 Total changes in operating liabilities 208,317 278,084 Total changes in operating assets and liabilities 208,317 278,084 Total changes in operating assets and liabilities 208,317 278,084 Total changes in operating assets and liabilities 208,317 278,084 Total changes in operating assets and liabilities 208,317 278,084 Total changes in operating assets at 61,000 442 1,126 Interest received 112,197 59,664 Interest received 112,197 59,664 Interest paid (16,772) (17,495) Increase paid (16,772) (17,495) Increase paid (16,772) (17,495) Increase paid (16,772) (1	Total changes in operating assets			(191,600)	
Accounts payable 34,871 (22,617) Other payable 31,243 (61,023) Other current liabilities (2,208) (4,675) Net defined benefit liability (2,208) (4,675) Net defined benefit liabilities 213,728 (86,484) Total changes in operating assets and liabilities 208,317 (278,084) Total changes in operating assets and liabilities 208,317 (278,084) Total changes in operating assets and liabilities 208,317 (329,113) Cash inflow generated from operations 1,330,286 800,342 Interest received 442 1,126 Dividends received (16,772) 59,466 Increst paid (16,772) (17,495) Increst paid (16,772) (17,495) Increst paid (16,772) (17,495) Increst paid (16,772) (17,495) Increst paid (16,752) (17,592) Increase in flows from operating activities (18,383) (18,383) Procecds from disposal of financial assets at fair value through other comprehensive income </td <td></td> <td></td> <td></td> <td>3,318</td>				3,318	
Other payable 31,243 (61,023) Other current liabilities (2,208) (4,675) Net defined benefit liability (3,712) (2,689) Total changes in operating liabilities 213,728 (86,484) Total adjustments 208,317 (278,884) Cash inflow generated from operations 1,330,286 800,342 Linterest received 442 1,126 Dividends received 112,197 59,664 Increst received (16,772) (17,495) Income taxes paid (195,916) 301,910 Net cash flows from operating activities 2,302,37 542,027 Cash flows from operating activities (195,916) 301,910 Net cash flows from operating activities (195,916) 301,910 Cash flows from (used in) investing activities (18,863) - Proceeds from disposal of financial assets at fair value through other comprehensive income - 70,172 Acquisition of investing activities (13,863) - Proceeds from disposal of financial assets at fair value through other comprehensive income (13,863)	Notes payable		198,672		
Other current liabilities (2,208) (4,675) Net defined benefit liability (3,712) (2,889) Total changes in operating liabilities 213,728 (86,484) Total changes in operating assets and liabilities 213,728 (86,484) Total changes in operating assets and liabilities 2248,067 (329,113) Cash inflow generated from operatings 1,330,286 800,342 Linterest received 442 1,126 Dividends received in presenting activities 112,197 59,646 Interest paid (16,772) (17,495) Income taxes paid (16,772) (17,495) Income taxes paid (16,772) (17,495) Income taxes paid (16,772) (17,495) Net cash flows from operating activities 1,230,237 542,027 Cash flows from disposal of financial assets at fair value through other comprehensive income 1 70,172 Acquisition of investments accounted for using equity method (13,863) - - 1,13 Increase in decrease in crefundable deposits paid (9,670) 8,393 -				(/ /	
Net defined benefit liabilities (3,712) (2,689) Total changes in operating labilities 213,728 (86,484) Total adjustments 248,067 (329,113) Cash inflow generated from operations 1,330,286 800,342 Interest received 442 1,126 Dividends received 112,197 59,964 Interest paid (16,772) (17,495) Income taxes paid (15,916) 301,910 Net cash flows from operating activities - 70,172 Cash flows from (used in investing activities - 70,172 Cash flows from disposal of financial assets at fair value through other comprehensive income - 70,172 Acquisition of investments accounted for using equity method (13,863) - Proceeds from disposal of financial assets at fair value through other comprehensive income (13,863) - Acquisition of investments accounted for using equity method (13,863) - Increase in from disposal of financial assets at fair value through other comprehensive income (12,847) (13,210) Proceeds from disposal of property, plant and equipment (56,552)					
Total changes in operating liabilities 213.728 (86.8484) Total changes in operating assets and liabilities 208.317 (278.084) Total adjustments 248.067 (329.113) Cash inflow generated from operations 1,330.286 800.342 Interest received 112,197 59.644 Dividends received 112,197 59.644 Interest paid (16,772) (17.495) Income taxes paid (105.7916) (301.910) Net cash flows from operating activities 1,230,237 542,027 Ensured from disposal of financial assets at fair value through other comprehensive income 7 70,172 Acquisition of investments accounted for using equity method 13,863 - Acquisition of property, plant and equipment 9 1,565.52 (155.962) Proceeds from disposal of property, plant and equipment 9 1,33 (1,224) (1,224) Increase in other financial assets 1 1 1,2228 (1,224) (1,224) (1,224) (1,224) (1,224) (1,224) (1,224) (1,224) (1,224)					
Total changes in operating assets and liabilities 208.317 (278.084) Total adjustments 248.067 (329.113) Cash inflow generated from operations 1,330,286 80.342 Interest received 1442 1,126 Dividends received 112,197 59.964 Interest paid (16,772) (17,495) Income taxes paid (16,772) (301,910) Net cash flows from operating activities 1,230,237 542,027 Cash flows from disposal of financial assets at fair value through other comprehensive income (13,863) 70,172 Acquisition of investments accounted for using equity method (13,863) - Acquisition of property, plant and equipment (56,552) (155,962) Proceeds from disposal of property, plant and equipment (9,670) 8,393 Acquisition of intangible assets (12,847) (13,210) Decrease in metional assets (19 (12,28 Increase in prepayments for business facilities (2,690) (789) (Increase) decrease in other mon-current assets (8,736) (10,566 Net cash flows used i					
Total adjustments 248.067 329.113 Cash inflow generated from operations 1,330,286 803,342 Interest received 442 1,126 Dividends received 112,197 59,964 Interest paid (16,772) (17,495) Income taxes paid (195,916) 301,910 Net cash flows from operating activities 1,230,237 542,027 Cash flows from disposal of financial assets at fair value through other comprehensive income (13,863) 70,172 Acquisition of investments accounted for using equity method (13,863) 1 Acquisition of property, plant and equipment (56,552) (155,962) Proceeds from disposal of property, plant and equipment 9,670 8,393 (Increase) decrease in refundable deposits paid 9,670 8,393 Acquisition of intangible assets 19 1,228 Increase in prepayments for business facilities 1,260 (789 (Increase) decrease in refundable deposits paid 9,670 789 (Increase) decrease in bort-framcial assets 1,12,210 1,228 Increase in prepayments for busi					
Cash inflow generated from operations 1,330,286 800,342 Interest received 442 1,126 Dividends received 112,197 59,964 Interest paid (16,772) (17,495) Income taxes paid (195,916) (301,910) Net cash flows from operating activities 1,230,237 542,027 Cash flows from disposal of financial assets at fair value through other comprehensive income - 70,172 Acquisition of investments accounted for using equity method (13,863) - Acquisition of property, plant and equipment (56,552) (155,962) Proceeds from disposal of property, plant and equipment - 13 (Increase) decrease in refundable deposits paid (9,670) 8,393 Acquisition of intangible assets (12,847) (13,210) Decrease in other financial assets (10,670) 8,393 Acquisition of intangible assets (10,670) 8,393 Increase in prepayments for business facilities (2,690) (789) (Increase) decrease in other financial assets (68,736) 10,656 Net cash flows used i	Total changes in operating assets and liabilities				
Interest received					
Dividends received Interest paid Interest paid Interest paid Interest paid (16,772) (17,495) 59,644 (16,772) (17,495) Income taxes paid (195,916) Net cash flows from operating activities 1,230,237 542,027 Cash flows from (used in) investing activities: Proceeds from disposal of financial assets at fair value through other comprehensive income - 70,172 Acquisition of investments accounted for using equity method (13,863) - Acquisition of property, plant and equipment (56,552) (155,962) Proceeds from disposal of property, plant and equipment 9,670 8,393 Acquisition of intangible assets (12,847) (13,210) Increase) decrease in refundable deposits paid (9,670) 8,393 Acquisition of intangible assets 190 1,228 Increase in prepayments for business facilities (2,690) (789) (Increase) decrease in other non-current assets (88,736) 10,656 Net cash flows used in investing activities (88,736) 10,656 Net cash flows used in financing activities (5,400,000) 5,400,000 Decrease in short-term loans 5,400,000 5,200,000 <t< td=""><td></td><td></td><td></td><td></td></t<>					
Interest paid (16,772) (17,495) Income taxes paid (195,916) (301,910) Net cash flows from operating activities 1,230,237 542,027 Cash flows from (used in) investing activities: *** 70,172 Proceeds from disposal of financial assets at fair value through other comprehensive income - 70,172 Acquisition of investments accounted for using equity method (13,863) - Acquisition of property, plant and equipment (56,552) (155,962) Proceeds from disposal of property, plant and equipment (9,670) 8,393 (Increase) decrease in refundable deposits paid (9,670) 8,393 Acquisition of intangible assets (12,847) (13,210) Decrease in other financial assets 190 1,228 Increase in prepayments for business facilities (2,690) (789) (Increase) decrease in other non-current assets (8,730) (10,4168) (79,499) Cash flows used in investing activities (164,168) (79,499) Cash flows used in process in short-term loans (5,400,000) (5,200,000) Proceeds from long-term borrowings </td <td></td> <td></td> <td></td> <td></td>					
Income taxes paid (195,916) (301,910) Net cash flows from operating activities 1,230,237 542,027 Cash flows from (used in) investing activities: 7 70,172 Proceeds from disposal of financial assets at fair value through other comprehensive income - 70,172 Acquisition of investments accounted for using equity method (13,863) - Acquisition of investments accounted for using equity method (56,552) (155,962) Proceeds from disposal of property, plant and equipment - 13 (Increase) decrease in refundable deposits paid (9,670) 8,393 Acquisition of intangible assets (12,847) (13,210) Decrease in other financial assets 190 1,228 Increase in prepayments for business facilities (2,690) 789 (Increase) decrease in other non-current assets (68,736) 10,656 Net cash flows used in investing activities (164,168) 79,499 Cash flows from (used in) financing activities (5,400,000) 5,400,000 Proceeds from long-term borrowings 5,400,000 5,200,000 Proceeds from long-term borrowings <td></td> <td></td> <td></td> <td></td>					
Net cash flows from operating activities 1,230,237 542,027 Cash flows from (used in) investing activities:					
Cash flows from (used in) investing activities: 70,172 Proceeds from disposal of financial assets at fair value through other comprehensive income - 70,172 Acquisition of investments accounted for using equity method (13,863) - (155,962) Acquisition of property, plant and equipment (56,552) (155,962) Proceeds from disposal of property, plant and equipment - 13 (10,670) 8,393 Acquisition of intangible assets (12,847) (13,210) Decrease in other financial assets 190 1,228 Increase in prepayments for business facilities (2,690) (789) (Increase) decrease in other non-current assets (68,736) 10,656 Net cash flows used in investing activities (164,168) (79,499) Cash flows from (used in) financing activities (5,400,000) 5,400,000 Decrease in short-term loans (5,400,000) 5,400,000 Decrease in short-term loans (5,400,000) 6,500,000 Repayments of long-term borrowings - (650,000) Increase in guarantee deposits received 78 - Payment of lease liabilities (5,544)					
Proceeds from disposal of financial assets at fair value through other comprehensive income - 70,172 Acquisition of investments accounted for using equity method (13,863) - Acquisition of property, plant and equipment (56,552) (155,962) Proceeds from disposal of property, plant and equipment - 13 (Increase) decrease in refundable deposits paid (9,670) 8,393 Acquisition of intangible assets (12,847) (13,210) Decrease in other financial assets 190 1,228 Increase in prepayments for business facilities (2,690) (789) (Increase) decrease in other non-current assets (68,736) 10,656 Net cash flows used in investing activities (164,168) (79,499) Cash flows from (used in) financing activities (5,400,000) 5,400,000 Decrease in short-term loans 5,400,000 5,400,000 Peroceeds from long-term borrowings - 700,000 Repayments of long-term borrowings - (650,000) Repayments of long-term borrowings - (55,000) Increase in guarantee deposits received 78 - Payment o					
Acquisition of property, plant and equipment (56,552) (155,962) Proceeds from disposal of property, plant and equipment - 13 (Increase) decrease in refundable deposits paid (9,670) 8,393 Acquisition of intangible assets (12,847) (13,210) Decrease in other financial assets 190 1,228 Increase in prepayments for business facilities (2,690) (789) (Increase) decrease in other non-current assets (68,736) 10,656 Net cash flows used in investing activities (164,168) (79,499) Cash flows from (used in) financing activities: 10,656 (5,400,000) 5,400,000 Decrease in short-term loans 5,400,000 5,400,000 5,400,000 6,200,000 Proceeds from long-term borrowings - (650,000) 6,500,000 7,000,000 6,000			-	70,172	
Proceeds from disposal of property, plant and equipment (Increase) decrease in refundable deposits paid - 13 (Increase) decrease in refundable deposits paid (9,670) 8,393 Acquisition of intangible assets (12,847) (13,210) Decrease in other financial assets 190 1,228 Increase in prepayments for business facilities (2,690) (789) (Increase) decrease in other non-current assets (68,736) 10,656 Net cash flows used in investing activities (164,168) (79,499) Cash flows from (used in) financing activities (164,168) (79,499) Cash flows from (used in) financing activities 5,400,000 5,400,000 Decrease in short-term loans 5,400,000 (5,200,000) Proceeds from long-term borrowings - (650,000) Repayments of long-term borrowings - (650,000) Increase in guarantee deposits received 78 - Payment of lease liabilities (5,544) (4,888) Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 710 - Net cash flows used in financing			(13,863)	-	
(Increase) decrease in refundable deposits paid (9,670) 8,393 Acquisition of intangible assets (12,847) (13,210) Decrease in other financial assets 190 1,228 Increase in prepayments for business facilities (2,690) (789) (Increase) decrease in other non-current assets (68,736) 10,656 Net cash flows used in investing activities (164,168) (79,499) Cash flows from (used in) financing activities: 5,400,000 5,400,000 Decrease in short-term loans 5,400,000 5,200,000 Procease in short-term borrowings - 700,000 Procease in guarantee deposits received 78 - Payment of lease liabilities (55,544) (4,888) Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 710 - Net cash flows used in financing activities (999,356) (749,487) Effect of exchange rate changes on cash and cash equivalents 66,710 (286,924) Net increase (decrease) in cash and cash equivalents 66,710 (286,924)			(56,552)	(155,962)	
Acquisition of intangible assets (12,847) (13,210) Decrease in other financial assets 190 1,228 Increase in prepayments for business facilities (2,690) (789) (Increase) decrease in other non-current assets (68,736) 10,656 Net cash flows used in investing activities (164,168) (79,499) Cash flows from (used in) financing activities: 5,400,000 5,400,000 Decrease in short-term loans 5,400,000 (5,200,000) Pecrease in short-term borrowings - (650,000) Repayments of long-term borrowings - (650,000) Increase in guarantee deposits received 78 - Payment of lease liabilities (5,544) (4,888) Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 710 - Net cash flows used in financing activities (999,356) (749,487) Effect of exchange rate changes on cash and cash equivalents 66,710 (286,924) Net increase (decrease) in cash and cash equivalents 66,710 (286,924) Cash and cash equivalents at beginning of period 194,591 481,515			-		
Decrease in other financial assets 190 1,228 Increase in prepayments for business facilities (2,690) (789) (Increase) decrease in other non-current assets (68,736) 10,656 Net cash flows used in investing activities (164,168) (79,499) Cash flows from (used in) financing activities: (164,168) (79,499) Increase in short-term loans 5,400,000 5,400,000 Decrease in short-term loans (5,400,000) (5,200,000) Proceeds from long-term borrowings - (650,000) Increase in guarantee deposits received 78 - Payment of lease liabilities (5,544) (4,888) Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 710 - Net cash flows used in financing activities (999,356) (749,487) Effect of exchange rate changes on cash and cash equivalents (3) 35 Net increase (decrease) in cash and cash equivalents 66,710 (286,924) Cash and cash equivalents at beginning of period 194,591 481,515					
Increase in prepayments for business facilities (2,690) (789) (Increase) decrease in other non-current assets (68,736) 10,656 Net cash flows used in investing activities (164,168) (79,499) Cash flows from (used in) financing activities: 5,400,000 5,400,000 Decrease in short-term loans 5,400,000 5,200,000 Proceeds from long-term borrowings - 700,000 Repayments of long-term borrowings - (650,000) Increase in guarantee deposits received 78 - Payment of lease liabilities (5,544) (4,888) Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 710 - Net cash flows used in financing activities (999,356) (749,487) Effect of exchange rate changes on cash and cash equivalents 66,710 (286,924) Net increase (decrease) in cash and cash equivalents 66,710 (286,924) Cash and cash equivalents at beginning of period 194,591 481,515					
(Increase) decrease in other non-current assets (68,736) 10,656 Net cash flows used in investing activities (164,168) (79,499) Cash flows from (used in) financing activities: Secondary of the property o					
Net cash flows used in investing activities (164,168) (79,499) Cash flows from (used in) financing activities: (164,168) (79,499) Increase in short-term loans 5,400,000 5,400,000 Decrease in short-term loans (5,400,000) (5,200,000) Proceeds from long-term borrowings - (650,000) Repayments of long-term borrowings - (650,000) Increase in guarantee deposits received 78 - Payment of lease liabilities (5,544) (4,888) Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 710 - Net cash flows used in financing activities (999,356) (749,487) Effect of exchange rate changes on cash and cash equivalents (3) 35 Net increase (decrease) in cash and cash equivalents 66,710 (286,924) Cash and cash equivalents at beginning of period 194,591 481,515					
Cash flows from (used in) financing activities: Increase in short-term loans 5,400,000 5,400,000 Decrease in short-term loans (5,400,000) (5,200,000) Proceeds from long-term borrowings - 700,000 Repayments of long-term borrowings - (650,000) Increase in guarantee deposits received 78 - Payment of lease liabilities (5,544) (4,888) Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 710 - Net cash flows used in financing activities (999,356) (749,487) Effect of exchange rate changes on cash and cash equivalents (3) 35 Net increase (decrease) in cash and cash equivalents 66,710 (286,924) Cash and cash equivalents at beginning of period 194,591 481,515					
Increase in short-term loans 5,400,000 5,400,000 Decrease in short-term loans (5,400,000) (5,200,000) Proceeds from long-term borrowings - 700,000 Repayments of long-term borrowings - (650,000) Increase in guarantee deposits received 78 - Payment of lease liabilities (5,544) (4,888) Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 710 - Net cash flows used in financing activities (999,356) (749,487) Effect of exchange rate changes on cash and cash equivalents (3) 35 Net increase (decrease) in cash and cash equivalents 66,710 (286,924) Cash and cash equivalents at beginning of period 194,591 481,515			(104,106)	(79,499)	
Decrease in short-term loans (5,400,000) (5,200,000) Proceeds from long-term borrowings - 700,000 Repayments of long-term borrowings - (650,000) Increase in guarantee deposits received 78 - Payment of lease liabilities (5,544) (4,888) Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 710 - Net cash flows used in financing activities (999,356) (749,487) Effect of exchange rate changes on cash and cash equivalents (3) 35 Net increase (decrease) in cash and cash equivalents 66,710 (286,924) Cash and cash equivalents at beginning of period 194,591 481,515	` , 0		5 400 000	5 400 000	
Proceeds from long-term borrowings - 700,000 Repayments of long-term borrowings - (650,000) Increase in guarantee deposits received 78 - Payment of lease liabilities (5,544) (4,888) Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 710 - Net cash flows used in financing activities (999,356) (749,487) Effect of exchange rate changes on cash and cash equivalents (3) 35 Net increase (decrease) in cash and cash equivalents 66,710 (286,924) Cash and cash equivalents at beginning of period 194,591 481,515			, , ,		
Repayments of long-term borrowings - (650,000) Increase in guarantee deposits received 78 - Payment of lease liabilities (5,544) (4,888) Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 710 - Net cash flows used in financing activities (999,356) (749,487) Effect of exchange rate changes on cash and cash equivalents (3) 35 Net increase (decrease) in cash and cash equivalents 66,710 (286,924) Cash and cash equivalents at beginning of period 194,591 481,515			-		
Increase in guarantee deposits received 78 -			_		
Payment of lease liabilities (5,544) (4,888) Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 710 - Net cash flows used in financing activities (999,356) (749,487) Effect of exchange rate changes on cash and cash equivalents (3) 35 Net increase (decrease) in cash and cash equivalents 66,710 (286,924) Cash and cash equivalents at beginning of period 194,591 481,515			78	-	
Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 710 - Net cash flows used in financing activities (999,356) (749,487) Effect of exchange rate changes on cash and cash equivalents (3) 35 Net increase (decrease) in cash and cash equivalents 66,710 (286,924) Cash and cash equivalents at beginning of period 194,591 481,515				(4,888)	
Dividends unclaimed by shareholders Net cash flows used in financing activities Effect of exchange rate changes on cash and cash equivalents Net increase (decrease) in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at beginning of period To compare the comparent of the comparent of the comparent of the comparent of the cash equivalents of the comparent of the comparent of the cash equivalent of t			` ' '	(994,599)	
Effect of exchange rate changes on cash and cash equivalents(3)35Net increase (decrease) in cash and cash equivalents66,710(286,924)Cash and cash equivalents at beginning of period194,591481,515	Dividends unclaimed by shareholders				
Net increase (decrease) in cash and cash equivalents66,710(286,924)Cash and cash equivalents at beginning of period194,591481,515					
Cash and cash equivalents at beginning of period 194,591 481,515					
			,	(286,924)	
Cash and cash equivalents at end of period \$\(\) \(\					
	Cash and cash equivalents at end of period	\$	261,301	194,591	



安侯建業群合會計師重務的 KPMG

台北市110615信義路5段7號68樓(台北101大樓) 68F., TAIPEI 101 TOWER, No. 7, Sec. 5, Xinyi Road, Taipei City 110615, Taiwan (R.O.C.) 電話 Tel + 886 2 8101 6666 傳真 Fax + 886 2 8101 6667 網址 Web home.kpmg/tw

Independent Auditors' Report

To the Board of Directors of TTY Biopharm Company Limited: **Opinion**

We have audited the consolidated financial statements of TTY Biopharm Company Limited and its subsidiaries ("the Group"), which comprise the consolidated balance sheets as of December 31, 2021 and 2020, the consolidated statements of comprehensive income, changes in equity and cash flows for the years then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies.

In our opinion, based on our audits and the report of another auditor (please refer to the Other Matter paragraph), the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Group as of December 31, 2021 and 2020, and its consolidated financial performance and its consolidated cash flows for the years then ended in accordance with the "Regulations Governing the Preparation of Financial Reports by Securities Issuers" and with the International Financial Reporting Standards ("IFRSs"), International Accounting Standards ("IASs"), Interpretations developed by the International Financial Reporting Interpretations Committee ("IFRIC") or the former Standing Interpretations Committee ("SIC") endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China.

Basis for Opinion

We conducted our audit in accordance with the Regulations Governing Auditing and Attestation of Financial Statements by Certified Public Accountants and the auditing standards generally accepted in the Republic of China. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Certified Public Accountants Code of Professional Ethics in Republic of China ("the Code"), and we have fulfilled our other ethical responsibilities in accordance with the Code. Based on our audits and the report of another auditor, we believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis of our opinion.

Other Matter

We did not audit the financial statements of PharmaEngine Inc, an associate of the Group, which represented investment in another entity accounted for using the equity method. Those statements were audited by another auditor, whose report has been furnished to us, and our opinion, insofar as it relates to the amounts included for certain equity-accounted investees, is based solely on the report of another auditor. The investment in the investee company constituting 9.40% and 9.37% of consolidated total assets as of December 31, 2021 and 2020, respectively, and the related share of profit of associates accounted for using the equity method constituting 7.01% and 8.94% of consolidated profit before tax for the years ended December 31, 2021 and 2020, respectively.

We have audited the financial statements of TTY Biopharm Company Limited as of and for the years ended December 31, 2021 and 2020, on which we have issued an unqualified opinion with an other matter section, thereon.



Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. Key audit matters for the consolidated financial statements are stated as follows:

1. Occurrence of revenue from selling pharmaceuticals and chemical drugs

Please refer to Notes 4(p) of the consolidated financial statements for the accounting principles on revenue recognition. Revenues are recognized by net values of contract prices, less sales returns and allowances, after controls of the products are transferred to the customers.

Key audit matters:

The Group's sales is mainly from the selling of pharmaceuticals and chemical drugs. Because the customers are diversity and numerous, it takes longer time to verify sales transactions. Therefore, the occurrence in sales transactions is one of the important issue in performing our audit procedures.

Auditing procedures performed:

- Testing the effectiveness of the design and implementing the internal control system of sales and collection operation;
- Testing the samples of sales transaction before and after the balance sheet date to ensure the correctness of sales revenue;
- Inspecting the related documents to ensure the adequacy and reasonableness of revenue recognition.

2. Inventory valuation

Please refer to Notes 4(h) and 5 of the consolidated financial statements for the accounting principles on the inventory valuation, significant accounting assumptions and judgments, and major sources of estimation uncertainty.

Key audit matters:

The Group's primary operating items are manufacturing and processing various kinds of pharmaceuticals. The pharmaceutical industry in Taiwan is susceptible to the constant amendments of its law, resulting in large price fluctuation of pharmaceutical products, which will affect the carrying value of inventories to exceed its net value. Because of these uncertainties, the Group's revenue and income may be effected by the price fluctuations. If the assessment of the net realizable value of the inventory is not appropriate, it will lead to a material misstatement of the financial statements.

Auditing procedures performed:

- Overviewing the stock ageing list, analyzing the movement of stock ageing by period;
- Obtaining the certificate documents to verify the correctness of the stock's expiry date; and
- Sampling the replacement cost and market price of inventories, and recalculating the net realizable value by marketing expense rate, to ensure the reasonableness of net realizable value adopted by the Group.



Responsibilities of Management and Those Charged with Governance for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with the Regulations Governing the Preparation of Financial Reports by Securities Issuers and IFRSs, IASs, IFRC, SIC endorsed and issued into effect by the Financial Supervisory Commission of the Republic of China, and for such internal control as management determines is necessary to enable the preparation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is responsible for assessing the Group's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

Those charged with governance (including the Audit Committee) are responsible for overseeing the Group's financial reporting process.

Auditor's Responsibilities for the Audit of the Consolidated Financial Statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the auditing standards generally accepted in the Republic of China will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with auditing standards generally accepted in the Republic of China, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- 1. Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- 2. Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Group's internal control.
- 3. Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- 4. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- 5. Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.



6. Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

The engagement partners on the audit resulting in this independent auditors' report are Yilien Han and Shu-Ying Chang.

KPMG

Taipei, Taiwan (Republic of China) March 9, 2022

Notes to Readers

The accompanying consolidated financial statements are intended only to present the consolidated statement of financial position, financial performance and cash flows in accordance with the accounting principles and practices generally accepted in the Republic of China and not those of any other jurisdictions. The standards, procedures and practices to audit such consolidated financial statements are those generally accepted and applied in the Republic of China.

The independent auditors' audit report and the accompanying consolidated financial statements are the English translation of the Chinese version prepared and used in the Republic of China. If there is any conflict between, or any difference in the interpretation of the English and Chinese language independent auditors' audit report and consolidated financial statements, the Chinese version shall prevail.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese)

TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Consolidated Balance Sheets

December 31, 2021 and 2020

(Expressed in Thousands of New Taiwan Dollar)

		Dece	ember 31, 20	21	December 31, 2	2020			Γ	ecember 31, 20)21	December 31, 20	020
	Assets	A	mount	%	Amount	%		Liabilities and Equity		Amount	%	Amount	%
	Current assets:							Current liabilities:					
1100	Cash and cash equivalents (note 6(a) and (t))	\$	2,222,253	24	2,223,730	24	2100	Short-term borrowings (note 6(k), (t) and 8)	\$	1,711,070	18	1,715,070	18
1120	Current financial assets at fair value through other comprehensive income		52,929	1	62,216	1	2130	Contract liabilities-current (note 6 (q))		39,769	-	16,285	-
	(note 6(b) and (t))						2150	Notes payable (note 6(t))		57,235	1	5,864	-
1150	Notes receivable, net (note 6(c) and (t))		37,646	-	33,766	-	2170	Accounts payable (note 6(t))		130,033	1	153,576	2
1170	Accounts receivable, net (note 6(c) and (t))		1,077,111	12	974,648	10	2219	Other payables (note 6(t))		522,085	6	497,016	5
1180	Accounts receivable due from related parties, net (note 6(c), (t) and 7)		22,996	-	24,854	-	2230	Current tax liabilities		150,392	2	110,127	1
1200	Other receivables, net (note 6(t) and 7)		13,622	-	16,483	-	2300	Other current liabilities		33,090	-	34,185	-
130X	Inventories (note 6(d))		955,011	10	1,110,501	12	2320	Long-term liabilities, current portion (note 6(l), (t) and 8)	_	407,905	5	16,543	
1410	Prepayments		46,960	1	64,146	1				3,051,579	33		
1476	Other current financial assets (note 6(j) and (t))		319,724	3	280,186	3		Non-current liabilities:					
1470	Other current assets (note 6(j))		1,151		8,011		2540	Long-term borrowings (note 6(l), (t) and 8)		4,146	-	412,051	4
			4,749,403	51	4,798,541	51	2570	Deferred tax liabilities (note 6(n))		260,519	3	271,826	3
	Non-current assets:						2640	Net defined benefit liability, non-current (note 6(m))		52,597	1	45,500	-
1517	Non-current financial assets at fair value through other comprehensive		197,204	2	226,241	3	2645	Guarantee deposits received (note 6(t))		2,429	-	2,430	-
	income (note 6(b) and (t))						2670	Other non-current liabilities (note 6(t))	_	157,961	2	2,268	
1550	Investments accounted for using the equity method, net (note 6(e))		1,233,023	13	1,221,736	13				477,652	6	734,075	7
1600	Property, plant and equipment (note 6(g))		2,511,393	28	2,584,740	28		Total liabilities	_	3,529,231	39	3,282,741	33
1760	Investment property, net (note 6(h))		135,689	1	137,270	1		Equity attributable to owners of parent (note 6(0)):	_				
1780	Intangible assets (note 6(i))		124,904	1	132,898	1	3100	Share capital		2,486,500	27	2,486,500	27
1840	Deferred tax assets (note 6(n))		63,723	1	61,798	1	3200	Capital surplus (note 6(e))		311,876	3	337,997	4
1915	Prepayments for business facilities		8,487	-	4,975	-	3310	Legal reserve		1,198,617	13	1,093,808	12
1920	Refundable deposits paid (note 6(t))		33,833	-	22,019	-	3320	Special reserve		133,709	1	110,154	1
1984	Other non-current financial assets (note 6(j), (t) and 8)		151,300	2	159,514	2	3350	Unappropriated retained earnings		1,235,223	13	1,555,016	17
1990	Other non-current assets (note 6(j))		87,506	1	11,077		3400	Other equity interest	_	(198,070)	(2)	(133,709)	<u>(1</u>)
			4,547,062	49	4,562,268	49		Equity attributable to owners of parent:		5,167,855	55	5,449,766	60
							36XX	Non-controlling interests (note 6(o))	_	599,379	6	628,302	7
								Total equity	_	5,767,234	61	6,078,068	67
	Total assets	\$	9,296,465	100	9,360,809	100		Total liabilities and equity	\$_	9,296,465	100	9,360,809	100

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Consolidated Statements of Comprehensive Income

For the years ended December 31, 2021 and 2020

(Expressed in Thousands of New Taiwan Dollar, Except for Earnings Per Share)

		_	2021 Amount	%	2020 Amount	%
4000	Operating revenue (note 6(q) and 7)	\$	4,535,610	100	4,221,836	100
5000	Operating costs (note 6(d), (i), (m) and 12)		1,767,630	39	1,617,062	38
	Gross profit	_	2,767,980	61	2,604,774	62
5910	Less: Unrealized profit (loss) from sales		8,161	_	6,734	_
5920	Add: Realized profit (loss) from sales		6,734	_	9,012	_
	Gross profit, net	_	2,766,553	61	2,607,052	62
6000	Operating expenses (note 6(i), (m), (r) and 12):	_	, <u>,</u>		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
6100	Selling expenses		921,732	21	983,415	23
6200	Administrative expenses		402,992	9	404,758	10
6300	Research and development expenses		287,595	6	261,597	6
6450	Expected credit losses (gains) (note 6(c))		13,582	_	(97)	_
	Total operating expenses	_	1,625,901	36	1,649,673	39
	Net operating income	_	1,140,652	25	957,379	23
	Non-operating income and expenses:	_	-,,		221,012	
7100	Interest income (note 6(s))		6,309	_	14,981	_
7010	Other income (note 6(s))		11,271	_	91,412	2
7020	Other gains and losses, net (note 6(s) and 7)		(187,051)	(4)	(5,699)	-
7050	Finance costs, net (note 6(s))		(18,985)	- (.)	(19,413)	_
7060	Share of profit of associates accounted for using the equity method, net (note 6(e))		135,184	3	162,865	4
7055	Total non-operating income and expenses	_	(53,272)	(1)	244,146	6
7055	Profit before tax	_	1,087,380	24	1,201,525	29
7950	Less: Income tax expenses (note 6(n))		264,811	6	222,848	5
1750	Profit for the period	_	822,569	18	978,677	24
8300	Other comprehensive income:	_	022,307	10	770,077	
8310	Components of other comprehensive income (loss) that will not be reclassified to profit or loss					
8311	(Losses) gains on remeasurements of defined benefit plans		(10,809)	_	7,920	_
8316	Unrealized (losses) gains from investments in equity instruments measured at fair value through other comprehensive		(21,094)	-	12,507	-
8320	Share of other comprehensive income (loss) of associates accounted for using equity method, components of other comprehensive income that will not be reclassified to profit or loss		6,112	-	(5,615)	-
8349	Income tax related to components of other comprehensive income that will not be reclassified to profit or loss	_	-			
	Components of other comprehensive (loss) income that will not be reclassified to profit or loss		(25,791)	-	14,812	-
8360	Components of other comprehensive income (loss) that will be reclassified to profit or loss	_				
8361	Exchange differences on translation		(87,454)	(2)	(82,652)	(2)
8370	Share of other comprehensive (loss) income of associates accounted for using the equity method, components of other comprehensive income that will be reclassified to profit or loss		(220)	-	282	-
8399	Income tax related to components of other comprehensive income that will be reclassified to profit or loss	_	17,540		16,480	
	Components of other comprehensive loss that will be reclassified to profit or loss	_	(70,134)	(2)	(65,890)	(2)
8300	Other comprehensive Loss	_	(95,925)	(2)	(51,078)	(2)
	Total comprehensive income for the period	\$_	726,644	16	927,599	22
	Profit attributable to:	_				
8610	Owners of parent	\$	831,894	18	924,178	23
8620	Non-controlling interests	_	(9,325)		54,499	1
		\$_	822,569	18	978,677	24
	Comprehensive income attributable to:	_				
	Owners of parent	\$	745,121	16	874,246	21
	Non-controlling interests		(18,477)		53,353	1
		\$_	726,644	16	927,599	22
	Earnings per share, net of tax (note 6(p))	_				
9750	Basic earnings per share	\$_		3.35		3.72
9850	Diluted earnings per share	\$		3.34		3.71
	· ·	=				

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Consolidated Statements of Changes in Equity For the years ended December 31, 2021 and 2020 (Expressed in Thousands of New Taiwan Dollar)

				Equity	attributable to own	ners of parent					
•						Tota	1 other equity inte	rest			
	Share capital		R	etained earnin	igs		Unrealized gains				
•	•	_					(losses) from				
							financial assets				
							measured at fair				
							value through		Total equity		
					Unappropriated	Exchange	other		attributable to	Non-	
	Ordinary	Capital	Legal	Special	retained		comprehensive	Total other	owners of	controlling	
	shares	surplus	reserve	reserve	earnings	translation	income	equity interest	parent	interests	Total equity
Balance on January 1, 2020	3 2,486,500	338,514	1,003,556	110,154	1,591,777	(80,724)		40,135	5,570,636	598,428	6,169,064
Net income	-	-	-	-	924,178	-	-	-	924,178	54,499	978,677
Other comprehensive income	_	_	_	_	7,920	(65,887)	8,035	(57,852)		(1,146)	(51,078)
Total comprehensive income			-	_	932,098	(65,887)	8,035	(57,852)		53,353	927,599
Appropriation and distribution of retained earnings:											
Legal reserve appropriated	_	-	90,252	_	(90,252)	_	-	-	-	_	_
Cash dividends of ordinary share	_	_	-	_	(994,599)		_	_	(994,599)	_	(994,599)
Other changes in capital surplus:					(***,***)				(** ',=**)		(** ',***)
Changes in equity of investments accounted for using the equity method	-	(517)	_	_	_	-	-	_	(517)	-	(517)
Changes in ownership interests in subsidiaries	-	-	_	_	-	_	-	_	-	6,600	6,600
Disposal of investments in equity instruments measured at fair value	_	-	_	_	115,992	_	(115,992)	(115,992)	-	-	-
through other comprehensive income					- ,		(-))	(- ,)			
Distribution of dividend by subsidiaries to non-controlling interests	_	_	-	-	-	-	_	-	-	(30,079)	(30,079)
Balance at December 31, 2020	2,486,500	337,997	1.093.808	110,154	1,555,016	(146,611)	12,902	(133,709)	5,449,766	628,302	6,078,068
Net income	-	-	-	-	831,894	-	-	-	831,894	(9,325)	822,569
Other comprehensive income	_	_	-	-	(10,809)	(70,162)	(5,802)	(75,964)	(86,773)	(9,152)	(95,925)
Total comprehensive income		-	-	_	821,085	(70,162)	(5,802)	(75,964)		(18,477)	726,644
Appropriation and distribution of retained earnings:											
Legal reserve appropriated	-	-	104,809	-	(104,809)	-	-	-	-	-	-
Special reserve appropriated	-	-	-	23,555		-	-	-	-	-	-
Cash dividends of ordinary share	-	-	-	-	(994,600)	-	-	-	(994,600)	-	(994,600)
Other changes in capital surplus:					, , ,				, , ,		
Changes in equity of investments accounted for using the equity method	-	(13,893)	-	-	-	-	-	-	(13,893)	-	(13,893)
Other changes in capital surplus	-	710	-	-	-	-	-	-	710	-	710
Difference between consideration value and carrying amount of subsidiaries	-	(13,155)	-	-	(6,311)	-	-	-	(19,466)	19,466	-
acquired or disposed		. , ,							, , ,		
Changes in ownership interests in subsidiaries	-	217	-	-	-	-	-	-	217	168	385
Disposal of investments in equity instruments measured at fair value	-	-	-	-	(11,603)	-	11,603	11,603	-	-	-
through other comprehensive income					(,)		, , , , , , , , , , , , , , , , , , , ,	,			
Distribution of dividend by subsidiaries to non-controlling interests	-	-	-	-	-	-	-	-	-	(30,080)	(30,080)
Balance on December 31, 2021	2,486,500	311,876	1,198,617	133,709	1,235,223	(216,773)	18,703	(198,070)	5,167,855	599,379	5,767,234

See accompanying notes to financial statements.

(English Translation of Consolidated Financial Statements Originally Issued in Chinese) TTY BIOPHARM COMPANY LIMITED AND SUBSIDIARIES

Consolidated Statements of Cash Flows

For the years ended December 31, 2021 and 2020

(Expressed in Thousands of New Taiwan Dollar)

Cash flows from (used in) operating activities 1,087,380 1,201,525			2021	2020	
Adjastments to reconcile profit (loss):	Cash flows from (used in) operating activities:	¢.	1 007 200	1 201 525	
Dependents to reconcile profit (loss):		Φ	1,067,360	1,201,323	
Expected redit losses (gams) 13.58 9.80 Net losses on financial assets or liabilities at fair value through profit or loss 13.58 6.75 Net losses on financial assets or liabilities at fair value through profit or loss 18.98 1.558 Interest expenses 18.98 1.558 Interest expenses 18.98 1.458 Dividend income 16.300 16.300 16.420 Shares of profit of investments accounted for using the equity method 15.18 18.000 16.200 Shares of profit of investments accounted for using the equity method 15.18 18.000 17.18 Losses (gains) on disposal of property, plant and equipment 736 23.1 Losses (gains) on disposal of investments 18.000 16.18 Impairment loss on non-financial assets 18.000 16.18 Realized profit from sales 18.000 16.200 Total adjustments to reconcle profit (loss) 18.000 18.000 Accounts receivable 18.000 18.000 18.000 Total changes in operating assets 18.000 18.000 Total changes in operating assets 18.000 18.000 Total changes in operating assets 18.000 18.000 Changes in operating liabilities 18.517 18.000 Changes in operating liabilities 18.517 18.000 Contract liabilities 18.000 18.000 Other purphe 18.000 18.000 18.000 Total changes in operating assets and liabilities 18.000 18.000 Total changes in operating assets and liabilities 18.000 18.000 Total changes in operating assets and liabilities 18.000 18.000 Total changes in operating assets and liabilities 18.000 18.000 Total changes in operating activities 18.000 1	Adjustments to reconcile profit (loss):				
Expected credit losses (gains) 13,882 967 Net losses on financial assets or flabilities at fair value through profit or loss 15,881 1558 Interest expenses 18,985 19413 Interest income 6,409 (14,943 14,944 14,943 14,944 14,9					
Net losses on financial assets or liabilities at fair value through profit or loss 1,8,985 19,413 Interest income					
Interest expenses			-		
Dividend income			18,985		
Shares of profit of investments accounted for using the equity method (13,184) (16,286) Losses (gains) on disposal of investments 205 (1,715) Impairment loss on non-financial assets 4,146 4,583 Unrealized profit from sales 8,161 6,734 Realized profit from sales 8,161 6,734 Realized profit from sales 8,161 6,734 Realized profit from sales 8,161 6,732 Changes of profit gas and its little 1,182 8,181 Changes in operating assets 1,183 6,542 Other receivable 1,183 6,642 Other receivables 1,1970 1,688 Total changes in operating sasets 19,707 1,688 Total changes in operating sasets 3,219 1,618 Contract liabilities 2,344 4,393 Contract liabilities 2,348 4,393 Contract liabilities 1,249 6,751 Other current liabilities 1,249 6,751 Total changes in operating sasets and liabilities 1,249 6,755					
Losses on disposal of propertry, plant and equipment					
Losses (gains) on disposal of investments			. , ,	(, ,	
Unrealized profit from sales 8,161 6,734 70,012 70 70 70 70 70 70 70 7					
Realized profit from sales					
Total adjustments to reconcile profit (loss) 58.509 (5.482) Changes in operating assets: Changes in operating assets: 3.880 9.53 Notes receivable (114,319) (3.64,22) 0.64,220 0.00 103,277 0.10 0.10 0.00 103,277 1.10 0.10 0.00 103,277 1.10 0.10 0.00 103,277 1.10 0.00 103,277 1.10 0.00 103,277 1.10 0.00 1.10 0.10 0.00 1.10 0.10 0.00 <th< td=""><td>Unrealized profit from sales</td><td></td><td></td><td></td></th<>	Unrealized profit from sales				
Changes in operating assets and liabilities: Changes in operating assets: Content receivables 2,009 103,277 10,277 11,275 11		-			
Notes receivable			20,202	(3,102)	
Accounts receivable (114,319) (36,422) Other receivables 2,009 103,272 Inventories 155,118 (251,804) Prepayments and other current assets 19,070 16,808 Total changes in operating assets 19,070 16,808 Contract liabilities 23,484 (93) Notes payable 195,171 4,408 Accounts payable 24,968 (75,511) Other current liabilities (12,027) (11,225) Net defined benefit liability (20,212) (2,689) Net defined benefit liabilities (30,481) (213,762) Total changes in operating assets and liabilities 20,481 (213,762) Cash inflow generated from operations 32,1955 (38,642) Cash inflow generated from operations 4,043 (30,422) Interest received 7,520 (31,483) Interest spaid (18,666) (19,496) Interest paid (20,223) (31,474) Net cash flows from operating activities 2,25,351 Cash inflows from ope					
Other receivables 2,000 103.277 Inventories 155.118 251.804 Prepayments and other current assets 15,018 251.804 Changes in operating liabilities: 16,008 16,008 Contract liabilities 23,484 (393) Notes payable 195,171 4,410 Accounts payable (20,371) 42,608 Other payable (20,371) (20,384) Other payable (20,277) (11,225) Net defined benefit liability (20,271) (11,225) Net defined benefit liabilities (20,481) (21,370) Total changes in operating assets and liabilities 263,446 (38,050) Total changes in operating liabilities 263,446 (38,050) Total changes in operating assets and liabilities 4,09,335 815,093 Interest received 6,375 14,981 Dividends received 6,375 14,981 Interest paid (8,060) (19,596) Increase in Mows from operating activities 2,362 Cash flows from (iscosal of fi					
Inventories					
Prepayments and other current assets					
Total changes in operating labilities: 38,635 (167,188) Contract liabilities 23,484 (393) Notes payable (20,3073) (26,534) Other payable (23,073) (26,534) Other payable 24,968 (77,511) Other current liabilities (10,27) (111,225) Net defined benefit liability (3,712) (2,688) Total changes in operating liabilities 203,446 (380,950) Total changes in operating sasets and liabilities 203,446 (380,950) Total adjustments 201,955 386,432 Cash inflow generated from operations 1,409,335 815,093 Interest received 6,375 14,981 Dividends received 79,520 27,347 Interest paid (18,666) (19,596) Income taxes paid (20,20,23) (31,474) Net cash flows from operating activities 23,484 23,484 Cash flows from (used in) investing activities 3,489 2,20,203 Proceeds from disposal of financial assets at fair value through other comprehensive income<					
Contract liabilities 23,484 (393) Notes payable 195,171 4,410 Other payable 24,968 (77,511) Other payable (12,027) (11,225) Net defined benefit liabilities (12,027) (11,225) Net defined benefit liabilities 204,811 (21,372) Total changes in operating labilities 204,811 (21,372) Total adjustments 205,346 (380,950) Total adjustments 1,409,335 815,093 Interest received 6,375 14,981 Dividends received 79,520 27,347 Interest paid (18,666) (19,596) Income taxes paid (20,223) (31,474) Net cash flows from operating activities 220,223 (31,474) Cash flows from (used in) investing activities (23,481) 25,234 Cash flows from disposal of financial assets at fair value through other comprehensive income (3,478) 2,2956 Proceeds from disposal of financial assets at fair value through profit or loss 2,000 2,2956 Proceeds from disposal of fi					
Notes payable 195,171 4,410 Accounts payable (23,073) (26,534) Other payable 24,968 (77,511) Other current liabilities (12,027) (11,225) Net defined benefit liability 3,712 (2,689) Total changes in operating assets and liabilities 204,811 (213,762) Total adjustments 32,1955 (386,432) Cash inflow generated from operations (4,90,335) 815,093 Interest received 6,375 14,981 Dividends received 79,520 27,347 Interest paid (18,666) (19,596) Income taxes paid (20,202) (31,1474) Net cash flows from questing activities (3,478) -22,255 Cash inflows fused in financial assets at fair value through other comprehensive income (3,478) -22,255 Proceeds from disposal of financial assets at fair value through profit or loss	Changes in operating liabilities:				
Accounts payable (23,073) (26,584) Other payable (24,968) (77,511) Other current liabilities (12,027) (111,225) Net defined benefit liabilities (23,712) (2,689) Total changes in operating liabilities 204,811 (213,762) Total adjustments 263,446 (380,950) Cash inflow generated from operations 1,409,335 815,093 Interest received 6,375 14,981 Dividends received 6,375 14,981 Interest received (20,223) (31,474) Net cash flows from operating activities (20,223) (31,474) Net cash flows from (used in) investing activities (20,223) (31,474) Net cash flows from (used in) investing activities (3,478) (2,223) Cash flow from disposal of financial assets at fair value through other comprehensive income (3,478) (2,223) Proceeds from disposal of financial assets at fair value through profit or loss 2,070 252,956 Proceeds from disposal of financial assets at fair value through profit or loss 2,080 (66,032) P					
Other payable Other current liabilities (7.511) (11.225) Net defined benefit liability (3.712) (2.889) Total changes in operating liabilities (20.34) (2.035) Total changes in operating liabilities 26.3446 (380,950) Total adjustments 321,955 (386,432) Cash inflow generated from operations (409,335) 815,003 Interest received 6,375 14,981 Dividends received (78,500) 27,347 Interest paid (18,666) (19,596) Income taxes paid (18,666) (19,596) Income taxes paid (20,023) (31,474) Net cash flows from operating activities 3 2,553 Cash flows from disposal of financial assets at fair value through other comprehensive income (3,478) - Proceeds from disposal of financial assets at fair value through profit or loss 2 4,316 Acquisition of property, plant and equipment (56,032) (16,317) Proceeds from disposal of property, plant and equipment 25 13 (Increase) decrease in other financial assets (31,324)					
Other current liabilities (11,207) (2,089) Net defined benefit liability (3,712) (2,089) Total changes in operating liabilities 204,811 (21,326) Total adjustments 263,446 (380,950) Cash inflow generated from operations 1,409,335 81,5093 Interest received 6,375 14,981 Dividends received 79,200 27,347 Interest paid (18,666) (19,596) Income taxes paid (20,20,23) 311,474 Net cash flows from operating activities 20,20,233 311,474 Cash flows from (used in) investing activities 36,375 4,346 Cash flows from disposal of financial assets at fair value through other comprehensive income 3,476 2,29,56 Proceeds from disposal of financial assets at fair value through profit or loss 20,707 252,956 Proceeds from disposal of financial assets at fair value through profit or loss 3 4,316 Acquisition of property, plant and equipment 25 13 (Increase) decrease in refundable deposits paid (1,383) (13,754) (Increa					
Net defined benefit liability (2,889) Total changes in operating liabilities 204,811 (21,3762) Total adjustments 263,446 (380,950) Cash inflow generated from operations 1,409,335 815,093 Interest received 6,375 14,981 Dividends received 6,375 14,981 Dividends received (18,666) (19,596) Income taxes paid (18,666) (19,596) Income taxes paid (20,223) (31,474) Net cash flows from Qused in) investing activities					
Total changes in operating assets and liabilities 263,446 (380,950) Total adjustments 321,955 (386,432) Cash inflow generated from operations 1,409,335 815,093 Interest received 6,375 14,981 Dividends received 79,520 27,347 Interest paid (18,666) (19,596) Income taxes paid (20,223) (31,1474) Net cash flows from operating activities 1,256,341 526,351 Adjustion of financial assets at fair value through other comprehensive income (3,478) 2 Proceeds from disposal of financial assets at fair value through other comprehensive income 3,476 2 Proceeds from disposal of financial assets at fair value through other comprehensive income 6,56,032 (167,317) Proceeds from disposal of financial assets at fair value through profit or loss - 4,316 Acquisition of property, plant and equipment 25 95 Proceeds from disposal of from collassets (11,820) 9,108 Acquisition of intangible assets (31,342) 15,52 Increase in prepayments for business facilities	Net defined benefit liability			(2,689)	
Total adjustments 321,955 (38,6432) Cash inflow generated from operations 1,409,335 815,093 Interest received 6,375 14,981 Dividends received 79,520 27,347 Interest paid (18,666) (19,596) Income taxes paid (20,223) 311,474 Net cash flows from operating activities -20,203 311,474 Cash flows from (used in) investing activities -3,25,341 256,351 Proceeds from disposal of financial assets at fair value through other comprehensive income 13,478 -7 Proceeds from disposal of financial assets at fair value through other comprehensive income 20,707 252,956 Proceeds from disposal of property, plant and equipment (56,032) (167,317) Acquisition of intangible assets (11,820) 9,108 Acquisition of intangible assets (13,34) (15,532) (Increase) decrease in refundable deposits paid (11,820) 9,108 Acquisition of intangible assets (31,324) 51,552 Increase in prepayments for business facilities (31,324) 61,552					
Cash inflow generated from operations 1,409,335 815,093 Interest received 6,375 14,981 Dividends received 79,520 27,347 Interest paid (18,666) (19,596) Income taxes paid (20,023) (311,474) Net cash flows from operating activities					
Interest received					
Dividends received 79,520 27,347 Interest paid (18,666) (19,596) Income taxes paid (220,223) (311,474) Net cash flows from operating activities 1,256,341 526,351					
Income taxes paid					
Net cash flows from (used in) investing activities 1,256,341 526,351 Cash flows from (used in) investing activities: 3,478 - Acquisition of financial assets at fair value through other comprehensive income 20,707 252,956 Proceeds from disposal of financial assets at fair value through profit or loss - 4,316 Acquisition of property, plant and equipment (56,032) (167,317) Proceeds from disposal of property, plant and equipment 25 13 (Increase) decrease in refundable deposits paid (11,820) 9,108 Acquisition of intangible assets (13,334) (13,754) (Increase) decrease in other financial assets (31,324) 51,552 Increase) decrease in other financial assets (83,33) 11,151 Net cash flows (used in) from investing activities (42,83) (789) (Increase) decrease in other non-current assets (88,735) 11,151 Net cash flows (used in) from investing activities (168,779) 147,236 Cash flows (used in) from investing activities (5,400,000) 5,240,000 Proceeds from long-term borrowings (5,400,000) 65,246,000 <td></td> <td></td> <td></td> <td></td>					
Cash flows from (used in) investing activities: (3,478) - Acquisition of financial assets at fair value through other comprehensive income 20,707 252,956 Proceeds from disposal of financial assets at fair value through profit or loss - 4,316 Acquisition of property, plant and equipment (56,032) (167,317) Proceeds from disposal of property, plant and equipment 25 13 (Increase) decrease in refundable deposits paid (11,820) 9,108 Acquisition of intangible assets (13,839) (13,754) (Increase) decrease in other financial assets (31,324) 51,552 Increase in prepayments for business facilities (4,283) (789) (Increase) decrease in other financial assets (68,735) 11,151 Increase in stream loans (68,735) 11,251 Net cash flows (used in) from investing activities (5,400,000) 5,400,000 Decrease in short-term loans 5,400,000 5,246,000 Proceeds from long-term borrowings (16,543) (663,650) Increase in other non-current liabilities - 72,000 Repayments of long-term borrowings <td></td> <td></td> <td></td> <td></td>					
Acquisition of financial assets at fair value through other comprehensive income (3,478) - Proceeds from disposal of financial assets at fair value through other comprehensive income - (4,316) Acquisition of property, plant and equipment (56,032) (167,317) Proceeds from disposal of property, plant and equipment 25 13 (Increase) decrease in refundable deposits paid (11,820) 9,108 Acquisition of intangible assets (13,339) (13,754) (Increase) decrease in other financial assets (31,324) 51,552 Increase) decrease in other financial assets (31,324) 51,552 (Increase) decrease in other financial assets (31,324) 51,552 (Increase) decrease in other financial assets (31,324) 51,552 (Increase) decrease in other financial assets (68,735) 11,151 (Increase) decrease in other non-current assets (68,735) 11,151 Net cash flows (used in) financing activities 5,400,000 5,400,000 Cash dividends paid to morrowings 5,400,000 5,2246,000 Proceeds from long-term borrowings (16,543) (663,650)		-	1,230,341	320,331	
Proceeds from disposal of financial assets at fair value through other comprehensive income 20,707 252,956 Proceeds from disposal of financial assets at fair value through profit or loss - 4,316 Acquisition of property, plant and equipment 25 13 (Increase) decrease in refundable deposits paid (11,820) 9,108 Acquisition of intangible assets (13,839) (13,754) (Increase) decrease in other financial assets (31,324) 51,552 Increase in prepayments for business facilities (4,283) (789) (Increase) decrease in other non-current assets (68,735) 11,151 (Increase) decrease in other non-current assets (68,735) 11,252 (Increase) decrease in other non-current assets (5,00,000) 5,400,000 (Increase) decrease in other non-current assets (5,00,000) 5,400,000 Net cash flows (used in) from investing activities 5,400,000 5,400,000 Decrease in short-term loans 5,400,000 5,246,000 Proceeds from long-term borrowings (16,543) (63,650) Repayments of long-term borrowings (16,543) (63,650) <			(3.478)	_	
Acquisition of property, plant and equipment (56,032) (167,317) Proceeds from disposal of property, plant and equipment 25 13 (Increase) decrease in refundable deposits paid (11,820) 9,108 Acquisition of intangible assets (13,839) (13,754) (Increase) decrease in other financial assets (31,324) 51,552 Increase in prepayments for business facilities (4,283) (789) (Increase) decrease in other non-current assets (168,735) 11,151 Net cash flows (used in) from investing activities (168,779) 147,236 Cash flows from (used in) financing activities 5,400,000 5,400,000 Decrease in short-term loans (5,404,000) 5,246,000 Proceeds from long-term borrowings (16,543) (663,650) Repayments of long-term borrowings (16,543) (663,650) Increase in other non-current liabilities - 1,120 Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders (30,080) (30,079) Cash dividends paid to non-controlling interests - 6,600 Net cash flows used in financing activities (1,044,				252,956	
Proceeds from disposal of property, plant and equipment (Increase) decrease in refundable deposits paid 25 13 (Increase) decrease in refundable deposits paid (11,820) 9,108 Acquisition of intangible assets (13,839) (13,754) (Increase) decrease in other financial assets (31,324) 51,552 Increase) decrease in other non-current assets (4,283) (789) (Increase) decrease in other non-current assets (68,735) 11,151 Net cash flows (used in) from investing activities (168,779) 147,236 Cash flows from (used in) financing activities: 5,400,000 5,400,000 Decrease in short-term loans 5,400,000 5,400,000 Decrease in short-term loans (5,404,000) (5,246,000) Proceeds from long-term borrowings (16,543) (663,650) Increase in other non-current liabilities - 1,120 Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders (30,080) (30,079) Cash dividends paid to non-controlling interests (30,080) (30,079) Change in non-controlling interests - <td></td> <td></td> <td>-</td> <td></td>			-		
(Increase) decrease in refundable deposits paid (11,820) 9,108 Acquisition of intangible assets (13,839) (13,754) (Increase) decrease in other financial assets (31,324) 51,552 Increase in prepayments for business facilities (4,283) (789) (Increase) decrease in other non-current assets (68,735) 11,151 Net cash flows (used in) from investing activities (168,779) 147,236 Cash flows from (used in) financing activities: 5,400,000 5,400,000 Increase in short-term loans 5,400,000 5,246,000 Proceeds from long-term borrowings 720,000 720,000 Repayments of long-term borrowings (16,543) (663,650) Increase in other non-current liabilities - 1,120 Cash dividends paid (994,600) (994,599) Cash dividends paid to non-controlling interests (30,080) (30,079) Cash dividends paid to non-controlling interests - 6,600 Net cash flows used in financing activities (1,044,128) (806,608) Effect of exchange rate changes on cash and cash equivalents (1,477) <	Acquisition of property, plant and equipment		. , ,		
Acquisition of intangible assets (13,839) (13,754) (Increase) decrease in other financial assets (31,324) 51,552 Increase in prepayments for business facilities (4,283) (789) (Increase) decrease in other non-current assets (68,735) 11,151 Net cash flows (used in) from investing activities (168,779) 147,236 Cash flows from (used in) financing activities: 5,400,000 5,400,000 Decrease in short-term loans (5,404,000) (5,246,000) Proceeds from long-term borrowings - 720,000 Repayments of long-term borrowings (16,543) (663,650) Increase in other non-current liabilities - 1,120 Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders (30,080) (30,079) Change in non-controlling interests (30,080) (30,079) Change in non-controlling interests - 6,600 Net cash flows used in financing activities (1,044,128) (806,608) Effect of exchange rate changes on cash and cash equivalents (44,911) (65,407) Net decrease in cash and cash equivalents (2,223,730) 2,422,158					
(Increase) decrease in other financial assets (31,324) 51,552 Increase in prepayments for business facilities (4,283) (789) (Increase) decrease in other non-current assets (68,735) 11,151 Net cash flows (used in) from investing activities (168,779) 147,236 Cash flows from (used in) financing activities: Total (168,779) 147,236 Increase in short-term loans 5,400,000 5,400,000 Decrease in short-term loans (5,404,000) (5,246,000) Proceeds from long-term borrowings - 720,000 Repayments of long-term borrowings (16,543) (663,650) Increase in other non-current liabilities - 1,120 Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 1,095 - Cash dividends paid to non-controlling interests (30,080) (30,079) Change in non-controlling interests (30,080) (30,079) Net cash flows used in financing activities (1,044,128) (806,608) Effect of exchange rate changes on cash and cash equivalents (44,911) (65,407) Net decrease in cash and cash equivalents (1,4					
(Increase) decrease in other non-current assets (68,735) 11,151 Net cash flows (used in) from investing activities (168,779) 147,236 Cash flows from (used in) financing activities: 3 11,151 Increase in short-term loans 5,400,000 5,400,000 Decrease in short-term loans (5,404,000) (5,246,000) Proceeds from long-term borrowings - 720,000 Repayments of long-term borrowings (16,543) (663,650) Increase in other non-current liabilities - 1,120 Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 1,095 - Cash dividends paid to non-controlling interests (30,080) (30,079) Change in non-controlling interests - 6,600 Net cash flows used in financing activities (1,044,128) (806,608) Effect of exchange rate changes on cash and cash equivalents (1,477) (198,428) Cash and cash equivalents at beginning of period 2,223,730 2,422,158	(Increase) decrease in other financial assets		(31,324)	51,552	
Net cash flows (used in) from investing activities (168,779) 147,236 Cash flows from (used in) financing activities: 5,400,000 5,400,000 Increase in short-term loans 5,400,000 5,400,000 Decrease in short-term loans (5,404,000) (5,246,000) Proceeds from long-term borrowings - 720,000 Repayments of long-term borrowings (16,543) (663,650) Increase in other non-current liabilities - 1,120 Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 1,095 - Cash dividends paid to non-controlling interests 30,080) (30,079) Change in non-controlling interests - 6,600 Net cash flows used in financing activities (1,044,128) (806,608) Effect of exchange rate changes on cash and cash equivalents (44,911) (65,407) Net decrease in cash and cash equivalents (1,477) (198,428) Cash and cash equivalents at beginning of period 2,223,730 2,422,158					
Cash flows from (used in) financing activities: Increase in short-term loans 5,400,000 5,400,000 Decrease in short-term loans (5,404,000) (5,246,000) Proceeds from long-term borrowings - 720,000 Repayments of long-term borrowings (16,543) (663,650) Increase in other non-current liabilities - 1,120 Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 1,095 - Cash dividends paid to non-controlling interests (30,080) (30,079) Change in non-controlling interests - 6,600 Net cash flows used in financing activities (1,044,128) (806,608) Effect of exchange rate changes on cash and cash equivalents (14,971) (65,407) Net decrease in cash and cash equivalents (1,477) (198,428) Cash and cash equivalents at beginning of period 2,223,730 2,422,158					
Increase in short-term loans 5,400,000 5,400,000 Decrease in short-term loans (5,404,000) (5,246,000) Proceeds from long-term borrowings - 720,000 Repayments of long-term borrowings (16,543) (663,650) Increase in other non-current liabilities - 1,120 Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 1,095 - Cash dividends paid to non-controlling interests (30,080) (30,079) Change in non-controlling interests - 6,600 Net cash flows used in financing activities (1,044,128) (806,608) Effect of exchange rate changes on cash and cash equivalents (44,911) (65,407) Net decrease in cash and cash equivalents (1,477) (198,428) Cash and cash equivalents at beginning of period 2,223,730 2,422,158			(100,779)	147,230	
Decrease in short-term loans (5,404,000) (5,246,000) Proceeds from long-term borrowings - 720,000 Repayments of long-term borrowings (16,543) (663,650) Increase in other non-current liabilities - 1,120 Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 1,095 - Cash dividends paid to non-controlling interests (30,080) (30,079) Change in non-controlling interests - 6,600 Net cash flows used in financing activities - 6,600 Effect of exchange rate changes on cash and cash equivalents (1,044,128) (806,008) Net decrease in cash and cash equivalents (1,477) (198,428) Cash and cash equivalents at beginning of period 2,223,730 2,422,158			5,400,000	5,400,000	
Repayments of long-term borrowings (16,543) (663,650) Increase in other non-current liabilities - 1,120 Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 1,095 - Cash dividends paid to non-controlling interests - 6,600 Net cash flows used in financing activities (1,044,128) (806,608) Effect of exchange rate changes on cash and cash equivalents (44,911) (65,407) Net decrease in cash and cash equivalents (1,477) (198,428) Cash and cash equivalents at beginning of period 2,223,730 2,422,158					
Increase in other non-current liabilities			-		
Cash dividends paid (994,600) (994,599) Dividends unclaimed by shareholders 1,095 - Cash dividends paid to non-controlling interests (30,080) (30,079) Change in non-controlling interests - 6,600 Net cash flows used in financing activities (1,044,128) (806,608) Effect of exchange rate changes on cash and cash equivalents (44,911) (65,407) Net decrease in cash and cash equivalents (1,477) (198,428) Cash and cash equivalents at beginning of period 2,223,730 2,422,158			(16,543)		
Dividends unclaimed by shareholders 1,095 - Cash dividends paid to non-controlling interests (30,080) (30,079) Change in non-controlling interests - 6,600 Net cash flows used in financing activities (1,044,128) (806,608) Effect of exchange rate changes on cash and cash equivalents (44,911) (65,407) Net decrease in cash and cash equivalents (1,477) (198,428) Cash and cash equivalents at beginning of period 2,223,730 2,422,158			(994.600)		
Change in non-controlling interests - 6,600 Net cash flows used in financing activities (1,044,128) (806,608) Effect of exchange rate changes on cash and cash equivalents (44,911) (65,407) Net decrease in cash and cash equivalents (1,477) (198,428) Cash and cash equivalents at beginning of period 2,223,730 2,422,158	Dividends unclaimed by shareholders			- ` ′	
Net cash flows used in financing activities(1,044,128)(806,608)Effect of exchange rate changes on cash and cash equivalents(44,911)(65,407)Net decrease in cash and cash equivalents(1,477)(198,428)Cash and cash equivalents at beginning of period2,223,7302,422,158	Cash dividends paid to non-controlling interests				
Effect of exchange rate changes on cash and cash equivalents(44,911)(65,407)Net decrease in cash and cash equivalents(1,477)(198,428)Cash and cash equivalents at beginning of period2,223,7302,422,158			(1.044.120)		
Net decrease in cash and cash equivalents(1,477)(198,428)Cash and cash equivalents at beginning of period2,223,7302,422,158	8				
Cash and cash equivalents at beginning of period 2,223,730 2,422,158			. , ,		
		\$			

TTY BIOPHARM COMPANY LIMITED

Year 2021 Profits Distribution Table

Unit: NTD

Item	Amount	Note
Unappropriated retained earnings of previous year	432,051,362	
Less: Year 2021 retained earnings adjustment	28,723,022	Re-measurement effects of defined benefit plans, the difference between share price and book value for affiliates, and recognized the gain (loss) of affiliates resulting from investments in equity instruments measured at fair value through other comprehensive income, and aforementioned gain (loss) is directly transferred to retained earnings.
Add: Year 2021 net profit after tax for the year	831,893,428	
Less: Appropriated as legal capital reserve (10%)	80,317,041	
Less: Appropriated as special reserve	64,360,882	
Retained earnings available for distribution as of December 31, 2021	1,090,543,845	
Allocation Items		
Cash Dividends to Shareholders	745,949,877	Cash dividend of NT\$3.0 per share
Unappropriated retained earnings as of December 31, 2021	344,593,968	

Note:

- 1. Total 248,649,959 outstanding common shares
- 2. Earnings distribution this time would be paid from earnings for year 2021 as priority.

Chairman of the Board: Lin, Chuan

Responsible Management: Lin, Chuan

Responsible Accountant: Wang, Shu-Wen

TTY BIOPHARM COMPANY LIMITED

Amendment Comparison Table of "Articles of Incorporation"

Before amendment	After amendment	Reason for amendment
Article 4	Article 4	Wording Modification.
The total reinvestment amount may	The total reinvestment amount may	
exceed 40% of the paid-in capital.	exceed 40% of the share capital.	
Reinvestment related matters shall be	Reinvestment related matters shall be	
approved by the board of directors and	approved by the board of directors and	
included in the meeting minutes of	included in the meeting minutes of	
board meetings before coming into	board meetings before coming into	
effect.	effect.	
Article 10	Article 10	Wording Modification.
Change to entitlement of shares would	Change to record in the shareholders'	
be ceased since 60 days prior to annual	list would be ceased since 60 days	
general meeting, 30 days prior to	prior to annual general meeting, 30	
extraordinary general meeting or 5	days prior to extraordinary general	
days prior record dare which decided	meeting or 5 days prior record dare	
by the company to distribute dividend,	which decided by the company to	
bonus or other benefit.	distribute dividend, bonus or other	
	benefit.	
Article 11	Article 11	Wording Modification.
Annual Shareholders Meetings shall	Annual Shareholders Meetings shall	
be convened by the board of directors	be convened at least once a year, by	
within 6 months upon the end of the	the board of directors within 6 months	
accounting year. Extraordinary	upon the end of the accounting year.	
Shareholders Meetings may be	Extraordinary Shareholders Meetings	
convened when deemed necessary in	may be convened when deemed	
accordance with relevant laws.	necessary in accordance with relevant	
	laws.	
Article 12.1	Article 13	Content unchanged, only
		article adjustment (from 12.1 to 13).
		,
Article 13	Article 14	Content unchanged, only
		article adjustment (from 13
		to 14).
Article 13.1	Article 15	Content unchanged, only
		article adjustment (from
		13.1 to 15).

The Company shall appoint 7 to 11 board directors. The number of directors elected shall be determined in a board meeting. And a candidate nomination system shall be adapted and the shareholders meeting shall elect directors from the list of candidates. They shall serve for a term of three years. And They may serve consecutive terms if reelected. At least of the aforementioned 7 to 11 directors and 20% of the aforementioned quota shall be aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 15 Content omitted Article 21 Content omitted Content omitted Article 21 Content omitted Content omitted Article 21 Content omitted Article 22 Content omitted Content omitted Content omitted Content omitted Article 20 Content unchanged, only article adjustment (from 14.4 to 20). Article 21 Content omitted Article 22 Content unchanged, only article adjustment (from 14.4 to 20). Article 23 Content unchanged, only article adjustment (from 14.4 to 20). Article 24 Content omitted Content omitted Content omitted Content omitted Article 26 Content omitted Content omitted Content omitted Content omitted Content unchanged, only article adjustment (from 15 to 21). Content unchanged, only article adjustment (from 15 to 21). Content unchanged, only article adjustment (from 15 to 21). Content unchanged, only article adjustment (from 15 to 21). Content unchanged, only article adjustment (from 15 to 21).	Before amendment	After amendment	Reason for amendment
The Company shall appoint 7 to 11 board directors. The number of directors elected shall be determined in a board meeting. And a candidate nomination system shall be adapted and the shareholders meeting shall elect directors from the list of candidates. They shall serve for a term of three years. And They may serve consecutive terms if reelected. At least of the aforementioned 7 to 11 directors and 20% of the aforementioned quota shall be aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 15 Content omitted Content omitted Content omitted Article 20 Content omitted Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Content omitted Content omitted Content omitted Article 21 Content unchanged, only article adjustment (from 14.4 to 20). Article 21 Content unchanged, only article adjustment (from 14.4 to 20). Article 21 Content omitted Content unchanged, only article adjustment (from 14.4 to 20). Article 21 Content unchanged, only article adjustment (from 14.4 to 20). Article 21 Content unchanged, only article adjustment (from 15 to 21). Article adjustment (from 15 to 21). Content unchanged, only article adjustment (from 15 to 21). Article 22 Content omitted Content omitted	Article 14	Article 16	1. Article adjustment (from
board directors. The number of directors elected shall be determined in a board meeting. And a candidate nomination system shall be adapted and the shareholders meeting shall elect directors from the list of candidates. They shall serve for a term of three years. And They may serve consecutive terms if reelected. At least of the aforementioned 7 to 11 directors and 20% of the aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 15 Content omitted Article 16 Content omitted Article 16 Content omitted Article 16 Content omitted Content omitted Article 20 Content unchanged, only article adjustment (from 14.4 to 20). Article 16 Content omitted Content omitted Article 16 Content omitted Content omitted Content omitted Article 20 Content unchanged, only article adjustment (from 14.4 to 20). Article 21 Content unchanged, only article adjustment (from 14.4 to 20). Article 16 Content omitted Content omitted Content omitted Content omitted Content omitted Content omitted Content unchanged, only article adjustment (from 14.4 to 20). Article 20 Content unchanged, only article adjustment (from 14.4 to 20). Article 21 Content unchanged, only article adjustment (from 15 to 21). Article 22 Content unchanged, only article adjustment (from 15 to 21). Article 23 Content unchanged, only article adjustment (from 15 to 21).	The Company shall appoint 7 to 11	The Company shall appoint 7 to 11	=
a board meeting. And a candidate nomination system shall be adapted and the shareholders meeting shall elect directors from the list of candidates. They shall serve for a term of three years. And They may serve consecutive terms if reelected. At least of the aforementioned 7 to 11 directors and 20% of the aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 15 Content omitted Article 16 Content omitted Content omitted Article 20 Content omitted Article 21 Content omitted Content omitted Article 22 Content omitted Content omitted Content omitted Content omitted Article 22 Content omitted Content omitted Content omitted Article 22 Content omitted Content omitted Content omitted Content omitted Article 22 Content omitted	board directors. The number of		2. Amendment was made
a board meeting. And a candidate nomination system shall be adapted and the shareholders meeting shall elect directors from the list of candidates. They shall serve for a term of three years. And They may serve consecutive terms if reelected. At least of the aforementioned 7 to 11 directors and 20% of the aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 15 Content omitted Article 20 Content omitted Article 16 Content omitted Article 21 Content omitted Article 16 Content omitted Article 22 Content unchanged, only article adjustment (from 14.4 to 20). Article 16 Content omitted Content omitted Article 22 Content unchanged, only article adjustment (from 14.4 to 20). Article 16 Content omitted Cont	directors elected shall be determined in	directors elected shall be determined in	for the purpose of
nomination system shall be adapted and the shareholders meeting shall elect directors from the list of candidates. They shall serve for a term of three years. And They may serve consecutive terms if reelected. At least of the aforementioned 7 to 11 directors and 20% of the aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 15 Content omitted Article 16 Content omitted Article 16 Content omitted Content omitted Article 16 Content omitted Article 16 Content omitted Content omitted Article 16 Content omitted Content omitted Content omitted Article 16 Content omitted Con	a board meeting. And a candidate	a board meeting. And a candidate	• •
and the shareholders meeting shall elect directors from the list of candidates. They shall serve for a term of three years. And They may serve consecutive terms if reelected. At least of the aforementioned 7 to 11 directors and 20% of the aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 15 Content omitted Article 15 Content omitted Article 16 Content omitted Content omitted Content omitted Article 16 Content omitted	_	1	
elect directors from the list of candidates. They shall serve for a term of three years. And They may serve consecutive terms if reelected. At least of the aforementioned 7 to 11 directors and 20% of the aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 15 Content omitted Article 15 Content omitted Article 16 Article 16 Content omitted Content omitted Article 16 Content omitted Content omitted Content omitted Article 16 Content omitted C		1	
candidates. They shall serve for a term of three years. And They may serve consecutive terms if reelected. At least of the aforementioned 7 to 11 directors and 20% of the aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 15 Content omitted Article 21 Content omitted Article 16 Content omitted Article 16 Content omitted Conten			·
of three years. And They may serve consecutive terms if reelected. At least of the aforementioned 7 to 11 directors and 20% of the aforementioned quota shall be aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Article 14.2 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 15 Article 15 Content omitted Article 20 Content omitted Article 16 Content omitted Article 20 Content omitted Content omitted Article 21 Content omitted Content omitted Article 3 Content omitted Content omitted Content omitted Article 20 Content omitted Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Content omitted Article 20 Content omitted Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Content omitted Article 20 Content omitted Content omitted Content omitted Content omitted Content omitted Article 21 Content omitted Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Content unchanged, only article adjustment (from 15 to 21). Content unchanged, only article adjustment (from 15 to 21).			
consecutive terms if reelected. At least of the aforementioned 7 to 11 directors and 20% of the aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.5 Content omitted Article 15 Content omitted Article 20 Content omitted Article 21 Content omitted Article 21 Content omitted Article 22 Content unchanged, only article adjustment (from 14.4 to 20). Content unchanged, only article adjustment (from 14.4 to 20). Content omitted Article 21 Content omitted Article 22 Content omitted Article 3 Content omitted Content omitted Article 21 Content omitted Content omitted Article 22 Content omitted Article 3 Content omitted Article 3 Content omitted Content omitted Content omitted Article 3 Content omitted Content omitted Content omitted Article 3 Content omitted Content omitte			r
At least of the aforementioned 7 to 11 directors and 20% of the aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.5 Content omitted Article 15 Article 20 Content omitted Article 21 Content omitted Article 21 Content omitted Article 21 Content omitted Article 21 Content omitted Article 22 Content omitted Article 23 Content omitted Article 24 Content omitted Article 25 Content omitted Article 26 Content omitted Article 27 Content omitted Article 28 Content omitted Article 34 Content omitted Article 45 Content omitted Article 29 Content omitted Article 34 Content unchanged, only article adjustment (from 14.3 to 19). Content unchanged, only article adjustment (from 14.4 to 20). Article 15 Content omitted Article 21 Content omitted Article 21 Content omitted Content omitted Article 34 Content unchanged, only article adjustment (from 15 to 21). Article 46 Content omitted Article 20 Content omitted Content omitted Article 21 Content unchanged, only article adjustment (from 15 to 21). Article 16 Article 16 Content omitted Content omitted Article 20 Content unchanged, only article adjustment (from 15 to 21).		1	
directors and 20% of the aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.5 Content omitted Article 14.6 Content omitted Article 14.7 Content omitted Article 14.8 Content omitted Article 14.9 Content omitted Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.5 Content omitted Article 20 Content omitted Article 21 Content omitted Article 21 Content omitted Article 21 Content omitted Article 23 Content omitted Content omitted Article 24 Content omitted Content omitted Article 25 Content omitted Content omitted Article 26 Content omitted Article 27 Content omitted Content omitted Article 3 Content unchanged, only article adjustment (from 14.4 to 20). Article 3 Content omitted Article 4 Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Article 21 Content unchanged, only article adjustment (from 15 to 21). Article 16 Article 16 Article 22 Content omitted Content unchanged, only article adjustment (from 15 to 21).			
aforementioned quota shall be independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.5 Content omitted Article 14.6 Content omitted Article 14.7 Content omitted Article 14.8 Content omitted Article 14.9 Content omitted Article 14.0 Content omitted Article 14.1 Content omitted Article 15 Content omitted Article 20 Content omitted Article 21 Content omitted Content omitted Article 21 Content omitted Content omitted Article 22 Content omitted Article 23 Content unchanged, only article adjustment (from 14.4 to 20). Article 15 Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Article 22 Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Article 22 Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Article 22 Content unchanged, only article adjustment (from 15 to 21).			
independent directors. The professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.5 Content omitted Article 14.6 Content omitted Article 14.7 Content omitted Article 14.8 Content omitted Article 14.9 Content omitted Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 20 Content omitted Article 21 Content omitted Article 21 Content omitted Article 21 Content unchanged, only article adjustment (from 14.3 to 19). Content unchanged, only article adjustment (from 14.4 to 20). Article 15 Content omitted Article 21 Content omitted Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Article 22 Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Article 22 Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Article 22 Content unchanged, only article adjustment (from 15 to 21).			
professional qualifications, shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.5 Content omitted Article 14.6 Content omitted Article 14.7 Content omitted Article 14.8 Content omitted Article 14.9 Content omitted Article 14.0 Content omitted Article 14.1 Content omitted Article 14.2 Content omitted Content omitted Article 14.4 Content omitted Article 14.5 Content omitted Article 15 Content omitted Article 21 Content omitted Content omitted Article 3 Content unchanged, only article adjustment (from 14.3 to 19). Content unchanged, only article adjustment (from 14.4 to 20). Article 15 Content omitted Article 21 Content omitted Content omitted Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Content omitted Article 3 Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Content omitted Content omitted Article 22 Content unchanged, only article adjustment (from 15 to 21). Content unchanged, only article adjustment (from 15 to 21).		_	
shareholding ratios, concurrent appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Content omitted Article 14.3 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.5 Content omitted Article 14.6 Content omitted Content omitted Article 14.7 Content omitted Content omitted Content omitted Article 14.4 Content omitted Article 14.5 Content omitted Content omitted Content omitted Article 14.6 Content omitted Content omitted Content omitted Article 20 Content omitted Content omitted Content omitted Content omitted Article 21 Content omitted Article 21 Content omitted Content	_	1	
appointment restrictions, nomination and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Content omitted Article 14.3 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 20 Content omitted Article 15 Content omitted Article 21 Content omitted Article 22 Content omitted Article 22 Content omitted Article 23 Content omitted Article 24 Content omitted Article 26 Content omitted Article 27 Content omitted Article 34 Content omitted Article 35 Content omitted Article 36 Content omitted Article 37 Content omitted Article 38 Content omitted Article 39 Content omitted Article 30 Content omitted Article 30 Content omitted Article 31 Content omitted Article 31 Content omitted Article 31 Content omitted Article 32 Content omitted Article 34 Content omitted Article 34 Content omitted Article 34 Content omitted Article 36 Content omitted Article 37 Content omitted Article 38 Content unchanged, only article adjustment (from 15 to 21). Article 36 Content omitted Article 37 Content omitted Article 38 Content omitted Article 30 Content omitted Article 30 Content omitted Article 30 Content omitted Article 31 Content omitted Article 31 Content omitted Article 32 Content unchanged, only article adjustment (from 15 to 21). Article 36 Content omitted Article 30 Content unchanged, only article adjustment (from 15 to 21).	1-	<u>-</u>	
and election methods, and other matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Content omitted Article 14.3 Content omitted Article 14.3 Content omitted Article 14.3 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.4 Content omitted Article 14.5 Content omitted Article 14.6 Content omitted Article 14.7 Content omitted Article 14.8 Content omitted Article 14.9 Content omitted Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 20 Content omitted Content omitted Article 21 Content omitted Article 21 Content omitted Article 21 Content omitted Article 21 Content omitted Article 22 Content omitted Content omitted Article 23 Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Content omitted Article 22 Content omitted Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Content omitted Article 22 Content omitted Content omitted Content omitted Content omitted Article 23 Content unchanged, only article adjustment (from 16	_	_	
matters for compliance shall be based on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 14.2 Content omitted Article 14.3 Content omitted Article 14.3 Content omitted Article 14.4 Content omitted Article 14.5 Content omitted Article 14.6 Content omitted Article 20 Content omitted Article 21 Content omitted Article 21 Content omitted Article 22 Content omitted Article 22 Content omitted Content omitted Article 22 Content omitted Content omitted Content omitted Article 22 Content omitted Content omitted Content omitted Article 22 Content omitted Content omitted Content omitted Article 23 Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Content omitted Content omitted Article 23 Content unchanged, only article adjustment (from 16 to 21).		1	
on relevant regulations of the authorities in charge of securities. Article 14.1 Content omitted Article 18 Content omitted Article 19 Content omitted Content omitted Article 19 Content omitted Content omitted Content omitted Article 19 Content omitted Content omitted Article 20 Content omitted Content omitted Article 15 Article 15 Article 21 Content omitted Article 21 Content omitted Content unchanged, only article adjustment (from 14.4 to 20). Content unchanged, only article adjustment (from 15 to 21). Article 16 Article 22 Content unchanged, only article adjustment (from 16 dipustment omitted article adjustment omitted article adjustment omitted article adjustment omitted article adjustment o	· ·	<u> </u>	
authorities in charge of securities. Article 14.1 Content omitted Content omitted Article 18 Content omitted Content omitted Article 19 Content omitted Content omitted Content omitted Article 19 Content omitted Content omitted Content omitted Article 19 Content omitted Content omitted Content omitted Article 20 Content omitted Article 21 Content omitted Article 21 Content omitted Article 21 Content omitted Content omitted Article 22 Content omitted Article 22 Content unchanged, only article adjustment (from 14.4 to 20). Article 15 Article 21 Content omitted Content omitted Article 22 Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Content omitted Article 22 Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Content omitted Article 22 Content unchanged, only article adjustment (from 16			
Article 14.1 Content omitted C	_	_	
Content omitted Content omitted Content omitted Content omitted Article 14.2 Content omitted Content omitted Content omitted Content omitted Content omitted Content omitted Article 19 Content omitted Content omitted Content omitted Content omitted Article 20 Content omitted Content omitted Article 21 Content omitted Content omitted Article 21 Content omitted Article 21 Content omitted Article 21 Content omitted Article 31 Content unchanged, only article adjustment (from 14.4 to 20). Article 15 Article 21 Content omitted Article 22 Content omitted Content omitted Content omitted Article 22 Content unchanged, only article adjustment (from 15 to 21). Content omitted Content unchanged, only article adjustment (from 15 to 21).			Content unchanged, only
Article 14.2 Content omitted C			
Content omitted Content omitted Content omitted Article 14.3 Content omitted Content omitted Content omitted Content omitted Content omitted Article 20 Content omitted Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Article 22 Content unchanged, only article adjustment (from 15 to 21). Article 16 Article 22 Content omitted Content omitted Content omitted Content omitted Content omitted Content unchanged, only article adjustment (from 16	Content similar		
Content omitted Content omitted Content omitted Article 14.3 Content omitted Content omitted Content omitted Content omitted Content omitted Article 20 Content omitted Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Article 22 Content unchanged, only article adjustment (from 15 to 21). Article 16 Article 22 Content omitted Content omitted Content omitted Content omitted Article 22 Content unchanged, only article adjustment (from 16	Article 14.2	Article 18	Content unchanged, only
Article 14.3 Content omitted C			
Article 14.3 Content omitted Content unchanged, only article adjustment (from 14.3 to 19). Content unchanged, only article adjustment (from 14.4 to 20). Article 15 Content omitted Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Content unchanged, only article adjustment (from 16			,
Content omitted Content omitted Content omitted Content omitted Article 14.4 Content omitted Content omitted Article 20 Content omitted Content omitted Content omitted Article 21 Content unchanged, only article adjustment (from 14.4 to 20). Content omitted Content omitted Content omitted Article 21 Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Content omitted Content omitted Content omitted Content unchanged, only article adjustment (from 16) Content omitted	Article 14.3	Article 19	<i>'</i>
Article 14.4 Content omitted Article 20 Content omitted Article 21 Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Article 22 Content omitted Article 22 Content omitted Content omitted Content omitted Content omitted Article 22 Content unchanged, only article adjustment (from 15 to 21). Article 16 Content omitted Content omitted Content omitted Content omitted	Content omitted	Content omitted	article adjustment (from
Article 14.4 Content omitted Article 20 Content omitted Article 15 Content omitted Article 21 Content omitted Content omitted Content omitted Article 21 Content omitted Content omitted Article 21 Content omitted Content omitted Article 22 Content unchanged, only to 21). Article 16 Content omitted Content omitted Content unchanged, only article adjustment (from 16)			-
Content omitted Content unchanged, only article adjustment (from 15 to 21). Content omitted Content omitted Content omitted Content unchanged, only article adjustment (from 16 content omitted) Content omitted	Auticle 14.4	Antiala 20	
Article 15 Content omitted Content omitted Article 21 Content omitted Content omitted Content omitted Article 16 Content omitted			article adjustment (from
Content omitted Content omitted Content omitted Content omitted article adjustment (from 15 to 21). Article 16 Content unchanged, only article adjustment (from 16	Content offitted	Content offitted	14.4 to 20).
to 21). Article 16 Content unchanged, only Content omitted Content omitted article adjustment (from 16	Article 15	Article 21	Content unchanged, only
Article 16 Content unchanged, only Content omitted Content omitted article adjustment (from 16	Content omitted	Content omitted	article adjustment (from 15
Content omitted Content omitted article adjustment (from 16			to 21).
	Article 16	Article 22	Content unchanged, only
to 22)	Content omitted	Content omitted	article adjustment (from 16
ω_{22} .			to 22).

Before amendment	After amendment	Reason for amendment
Article 16.1 Content omitted	Article 23 Content omitted	Content unchanged, only article adjustment (from 16.1 to 23).
Article 17 Content omitted	Article 24 Content omitted	Content unchanged, only article adjustment (from 17 to 24).
Article 18 Content omitted	Article 25 Content omitted	Content unchanged, only article adjustment (from 18 to 25).
Article 19 Content omitted	Article 26 Content omitted	Content unchanged, only article adjustment (from 19 to 26).
1 to December 31. Accounts shall be settled at the end of every year. Upon settlement of accounts, the board of directors shall create the following documents and forms which These documents and the review report shall be submitted to the shareholders meeting for ratification in accordance with relevant laws. 1. Business report. 2. Financial statement.	Article 27 The accounting year runs from January 1 to December 31. Accounts shall be settled at the end of every year. Upon settlement of accounts, the board of directors shall create the following documents and forms which These documents and the review report shall be submitted to the annual general meeting for ratification in accordance with relevant laws. 1. Business report. 2. Financial statement. 3. Surplus allocation or loss make-up proposal.	 Content unchanged, only article adjustment (from 20 to 27). Wording modification.
Article 21 Content omitted.	Article 28 Content omitted.	Content unchanged, only article adjustment (from 21 to 28).

Before amendment	After amendment		Reason for amendment
Article 22 Where surpluses are recorded upon annual settlement of accounts, 10% shall be appropriated as legal reserve upon payment of taxes and making up for previous losses in accordance with relevant laws unless the Legal Reserve has reached the Company's total paidin capital. The remaining profits shall be set aside for special reserve in accordance with the laws, regulations, or the business requirements. Any further remaining profits plus unappropriated earnings shall be distributed in accordance with the proposal submitted by the Board for approval at a shareholders' meeting.	and recover accumulated losses before contributing 10% for legal reserve. However, this shall not be applied if legal reserve hereto has already reached the amount of share capital. After residual amount from aforementioned calculation is added to unappropriated earnings from previous period, a contribution or reversal to special reserved shall then be conducted in accordance with regulations or competent authority's requirements. At the end of each fiscal year, the Board of Directors will propose an earnings distribution based on considerations of the Company's profits, capital and financial structure, future business needs, accumulated earnings and legal reserve, market competition conditions as well as shareholders' interests. The proposal		Article adjustment (from 22 to 29). Related consideration factors on earnings distribution prescribed in original Article 23 are related to contents of this article, and therefore these factors are now moved to the latter part of paragraph 1 of this article. For the purpose of explaining basis for legal reserve contribution, paragraph 2 is hereby added accordingly in accordance with official letter from the Ministry of Economic Affairs dated January 9th, 2020 under reference number of Jin-Shang-Zi No.10802432410l. Wording modification.
Article 23 In accordance with stock dividend allocation procedures, the board of directors shall formulate surplus distribution proposals in consideration of company profits, capital and financial structure, future business demands, accumulated surplus, legal reserves, and market competition conditions at the end of every year. These proposals shall be implemented upon resolution of the shareholders meeting.		facthing the factor of the fac	elated consideration etors on earnings stribution prescribed in s Article are related to vised contents of Article , and therefore these etors are now moved to e latter part of paragraph 1 Article 29.

	Article 30	1	
The Company shall adopt a dividend		1.	Article adjustment (from
	The Company adopts principle of		24 to 30).
		2.	Percentages for dividend
financial structure and safeguard	dividend. In the event of surplus from		contribution and cash
investor rights and interests. A	the Company's fiscal account, a		dividend distribution are
minimum of 50% of distributable	contribution of not lower than 70% of		modified, and paragraph
surpluses in the respective year shall	the balance amount after tax payment,		1 is modified through
be distributed as stock dividends. A	accumulated loss recovery,		adjustments on
minimum of 70% of the allocated	contribution of legal reserve and		descriptions of the
stock dividends in the respective year	contribution or reversal of special		article contents.
shall be distributed in form of cash	earnings reserve as required by laws	3.	Paragraph 2 of the article
dividends.	shall be made to serve as shareholder		hereto is modified based
	dividend in accordance with		on stability principles for
	requirements of Article 29. This can be		the Company's financial
	conducted in cash or stocks.		structure and practical
	Percentage for cash dividend		needs.
	distribution shall not lower than 70%	4.	Paragraph 3 of the article
	of the total dividend amount. Based on		hereto is added in
	the Company's principles of stability		accordance with
	for financial structure and dividend		requirements prescribed
	balance, the Company may distribute		on Paragraph 5, Article
	all or part of reserve or retained		240 of the Company Act.
	earnings from previous period in		
	accordance with laws or competent		
	authority's requirements in the event		
	that there is no surplus for distribution		
	in current period, or there is surplus		
	but surplus amount is obviously lower		
	than the Company's surplus actually		
	distributed in the previous year. In the		
	event of disposal of real estate, equity		
	investments or intangible assets in the		
	current year, all or a portion of		
	difference between disposal amount		
	and acquisition cost, or income		
	received from litigation or commercial		
	dispute, can be retained accordingly.		
	Restrictions on distribution percentage		
	prescribed in paragraph 1 of this		
	article shall not apply. In the event that		
	the Company distributes all or a		
	portion of dividend, bonus or legal		
	reserve or capital reserve in cash, the		

Before amendment	After amendment	Reason for amendment
	Board of Directors Meeting is hereby authorized to execute this after two-thirds of directors attend Board of Directors Meeting and consent from half of attending directors is obtained, and the Annual General Meeting shall be reported accordingly.	
Article 25	Article 31	Content unchanged, only
Content omitted	Content omitted	adjustment of articles (from 25 to 31).
Article 26	Article 32	Content unchanged, only
Content omitted	Content omitted	article adjustment (from 26 to 32).
Article 27	Article 33	Content unchanged, only
Content omitted	Content omitted	article adjustment (from 27 to 33).
Article 28	Article 34	Article adjustment.
These articles of incorporation were	These articles of incorporation were	2. Adding the date of the
formulated on June 23, 1960.	formulated on June 23, 1960.	latest amendment.
They were amended for the first time on	They were amended for the first time on	
June 17, 1966.	June 17, 1966. :	
They were amended for the thirty-nine	They were amended for the thirty-nine	
time on June 12, 2020.	time on June 12, 2020.	
	They were amended for the forty time on May 26, 2022.	

TTY BIOPHARM COMPANY LIMITED

Amendment Comparison Table of "Procedures for Acquisition or Disposal of Assets"

Before amendment	After amendment	Reason for amendment
Article 6	Article 6	Amendment was made in
Acquisition of Expert Report:	Acquisition of Expert Report:	accordance with the revision
1. In acquiring or disposing of real		of "Regulations Governing
property or equipment or right-of-	property or equipment or right-of-	with Acquisition and
use assets where the transaction		Disposal of Assets by Public
amount reaches 20 percent of the		Companies".
Company's paid-in capital or	Company's paid-in capital or	1. Given respective
NT\$300 million or more, the	NT\$300 million or more, the	associations, to which
Company, unless transacting with a	Company, unless transacting with a	external experts belong,
domestic government institution,	domestic government institution,	have established related
engaging others to build on its own	engaging others to build on its own	requirements on their
land, engaging others to build on	land, engaging others to build on	responsible businesses,
rented land, or acquiring or	rented land, or acquiring or	preface of paragraph 6
disposing of equipment or right-of-	disposing of equipment or right-of-	hereto is hereby
use assets for business use, shall	use assets for business use, shall	amended accordingly to
obtain an appraisal report prior to	obtain an appraisal report prior to	regulate that assessment
the date of occurrence of the event	the date of occurrence of the event	report or opinions issued
from a professional appraiser and	from a professional appraiser and	by professional
shall further comply with the	shall further comply with the	appraisers and their
following provisions:	following provisions:	employees, accountants,
(1) Where due to special	(1) Where due to special	lawyers or securities
circumstances it is necessary to	circumstances it is necessary to	underwriters shall be
give a limited price, specified	give a limited price, specified	conducted not only in
price, or special price as a	price, or special price as a	accordance with various
reference basis for the	reference basis for the	items prescribed in
transaction price, the	transaction price, the	current paragraph 6 but
transaction shall be submitted	transaction shall be submitted	also self-discipline rules
for approval in advance by the	for approval in advance by the	from respective
board of directors, and the same	board of directors, and the same	associations to which
procedure shall be followed for	procedure shall be followed for	they belong.
any future changes to the terms	,	2. Aforementioned external
and conditions of the	and conditions of the	expert's undertaking or
transaction.	transaction.	execution of appraisal
(2) Where the transaction	(2) Where the transaction amount	report or fairness
amount is NT\$1 billion or	is NT\$1 billion or more,	opinion cases in
more, appraisals from two or	appraisals from two or more	accordance with
more professional appraisers	professional appraisers shall be	requirements of
shall be obtained.	obtained.	operation procedures

Before amendment

- (3) Where any one of the following circumstances applies with respect to the professional appraiser's appraisal results, unless all the appraisal results for the assets to be acquired are higher than the transaction amount, or all the appraisal results for the assets to be disposed of are lower than the transaction amount, a certified public accountant shall be engaged to perform the appraisal in accordance with the provisions of Statement of Auditing Standards No. 20 published by the ROC Accounting Research and Development Foundation (ARDF) and render a specific opinion regarding the reason for the discrepancy and the appropriateness of the transaction price:
 - (a) The discrepancy between the appraisal result and the transaction amount is 20 percent or more of the transaction amount.
 - (b) The discrepancy between the appraisal results of two or more professional appraisers is 10 percent or more of the transaction amount.
- (4) No more than 3 months may elapse between the date of the appraisal report issued by a professional appraiser and the contract execution date; provided, where the publicly announced current value for the same period is used and

After amendment

- (3) Where any one of the following circumstances applies with respect to the professional appraiser's appraisal results, unless all the appraisal results for the assets to be acquired are higher than the transaction amount, or all the appraisal results for the assets to be disposed of are lower than the transaction amount, a certified public accountant shall be engaged to perform the appraisal and render a specific opinion regarding the reason for the discrepancy and the appropriateness of the transaction price:
 - (a) The discrepancy between the appraisal result and the transaction amount is 20 percent or more of the transaction amount.
 - (b) The discrepancy between the appraisal results of two or more professional appraisers is 10 percent or more of the transaction amount.
- (4) No more than 3 months may elapse between the date of the appraisal report issued by a professional appraiser and the contract execution date; provided, where the publicly announced current value for the same period is used and not more than 6 months have elapsed, an opinion may still be issued by the original professional appraiser.
- 2. Where the Company acquires or disposes of securities shall, prior to

- Reason for amendment
 - hereto is not an audit task on financial statement. Accordingly, words of "audit" cases prescribed in subparagraph 2 of paragraph 6 are hereby amended to "execution" cases.
- 3. Under considerations of actual assessment sourced from utilized material, parameters and information, and being referred related words regarding information source and suitability and fairness of parameters prescribed on item 3-5, subparagraph 4, paragraph 4, Article 9 of Regulations Governing the Preparation of Financial Reports by Securities Issuers, explanation from Accounting Research and Development Foundation's letter dated December 25th, 2014 under reference number of (103) Ji-Mi-Zi No. 0000000298 and Article 27. No. 8 of Statements of Valuation Standards, words prescribed on subparagraph 3 and 4 of paragraph 6 are hereby amended accordingly in order to be in line with reality.

Before amendment

After amendment

Reason for amendment

- not more than 6 months have elapsed, an opinion maystill be issued by the original professional appraiser.
- 2. Where the Company acquires or disposes of securities shall, prior to the date of occurrence of the event. obtain financial statements of the issuing company for the most recent period, certified or reviewed by a certified public accountant, for reference in appraising the transaction price, and if the dollar amount of the transaction is 20 percent of the Company's paid-in capital or NT\$300 million or more, the Company shall additionally engage a certified public accountant prior to the date of occurrence of the event to provide an opinion regarding the reasonableness of the transaction price. If the CPA needs to use the report of an expert as evidence, the 3. Where the Company acquires or CPA shall do so in accordance with the provisions of Statement of Auditing Standards No. 20 published by the ARDF. This requirement does not apply, however, to publicly quoted prices of securities that have an active market, or where otherwise provided by regulations of the Financial Supervisory Commission (FSC).
- 3. Where the Company acquires or disposes of intangible assets or right-of-use assets and the transaction amount reaches 20 percent or more of paid-in capital or NT\$300 million or more, except in transactions with a domestic government institution, the

- the date of occurrence of the event. 4. obtain financial statements of the issuing company for the most recent period, certified or reviewed by a certified public accountant, for reference in appraising the transaction price, and if the dollar amount of the transaction is 20 percent of the Company's paid-in capital or NT\$300 million or more, the Company shall additionally engage a certified public accountant prior to the date of occurrence of the event to provide an opinion regarding the reasonableness of the transaction price. This requirement does not apply, however, to publicly quoted prices of securities that have an active market, or where otherwise provided by regulations of the Financial Supervisory Commission (FSC).
- disposes of intangible assets or right-of-use assets and the transaction amount reaches 20 percent or more of paid-in capital or NT\$300 million or more, except in transactions with a domestic government institution, the Company shall engage a certified public accountant prior to the date of occurrence of the event to render an opinion on the reasonableness of the transaction price.
- 4. Omitted.
- 5. Omitted.
- 6. When issuing an appraisal report or opinion, the personnel referred to in the preceding paragraph shall comply with the self- discipline rules of its association and the

Paragraph 6 of the article hereto has already added requirements requesting external expert to comply with his or her association's the selfdiscipline rules when issuing opinions. This has already encompassed procedures to be implemented by accountants when issuing opinions. Accordingly, words requiring accountants to comply with requirements on No. 20 of Statements of **Auditing Standards** published by Accounting Research and Development Foundation prescribed on subparagraph 3 of paragraph 1, paragraph 2 and 3 are hereby deleted.

	Before amendment	After amendment	Reason for amendment
	Company shall engage a certified	following:	
	public accountant prior to the date	(1) Prior to accepting a case, they	
	of occurrence of the event to render	shall prudently assess their own	
	an opinion on the reasonableness of		
	the transaction price; the CPA shall	practical experience, and	
	comply with the provisions of	independence.	
	Statement of Auditing Standards	(2) When executing, they shall	
	No. 20 published by the ARDF.	appropriately plan and execute	
4.	Omitted.	adequateworking procedures, in	
5.	Omitted.	order to produce a conclusion	
6.	When issuing an appraisal report or	and use the conclusion as the	
0.	opinion, the personnel referred to	basis for issuing the report or	
	in the preceding paragraph shall	opinion. The related working	
	comply with the following:	procedures, data collected, and	
	(1) Prior to accepting a case, they	conclusion shall be fully and	
	shall prudently assess their own	accurately specified in the case	
	professional capabilities,	working papers.	
	practical experience, and	(3) They shall undertake an item-	
	independence.	by-item evaluation of the	
	(2) When examining a case, they	adequacy, and reasonableness	
	shall appropriately plan and	of the sources of data used, the	
	execute adequateworking	parameters, and the	
	procedures, in order to produce	information, as the basis for	
	a conclusion and use the	issuance of the appraisal report	
	conclusion as the basis for	or the opinion.	
	issuing the report or opinion.	(4) They shall issue a statement	
	The related working	attesting to the professional	
	procedures, data collected, and	competence and independence	
	conclusion shall be fully and	of the personnel who prepared	
	accurately specified in the case	the report or opinion, and that	
	working papers.	they have evaluated and found	
	(3) They shall undertake an item-	that the information used is	
	by-item evaluation of the	reasonable and adequate, and	
	comprehensiveness, accuracy,	that they have complied with	
	and reasonableness of the	applicable laws and regulations.	
	sources of data used, the	7. Omitted.	
	parameters, and the		
	information, as the basis for		
	issuance of the appraisal report		
	or the opinion.		
	(4) They shall issue a statement		
	attesting to the professional		
	competence and independence		

Before amendment	After amendment	Reason for amendment
of the personnel who prepared the report or opinion, and that they have evaluated and found that the information used is reasonable and accurate, and that they have complied with applicable laws and regulations.		
7. Omitted.		
 Article 8 Related Party Transactions: 1. Omitted. 2. Assessment and Operation Procedures: (1) When the Company intends to acquire or dispose of real property or right-of-use assets from or to a related party, or when it intends to acquire or dispose of assets other than real property or right-of-use assets from or to a related party and the transaction amount reaches 20 percent or more of paid-in capital, 10 percent or more of the Company's total assets, or NT\$300 million or more, except in trading of domestic government bonds or bonds under repurchase and resale agreements, 	Article 8 Related Party Transactions: 1. Omitted. 2. Assessment and Operation Procedures: (1) When the Company intends to acquire or dispose of real property or right-of-use assets from or to a related party, or when it intends to acquire or dispose of assets other than real property or right-of-use assets from or to a related party and the transaction amount reaches 20 percent or more of paid-in capital, 10 percent or more of the Company's total assets, or NT\$300 million or more, except in trading of domestic government bonds or bonds under repurchase and resale agreements,	Amendment was made in accordance with the revision of "Regulations Governing with Acquisition and Disposal of Assets by Public Companies". 1. For Paragraph 2 of original article, subparagraph 2 is now moved to subparagraph 6 while subparagraph 3 to subparagraph 5 are moved to subparagraph 2 to subparagraph 4. 2. Subparagraph 5 is added: (1) For the purpose of enhancing management on related party transaction and protecting minority
or subscription or redemption of domestic money market funds		

(a) The purpose, necessity and anticipated benefit of the acquisition or

issued by adomestic securities

(SITE), the Company may not

transaction contract or make a

matters have been approved by

the Audit Committee and board

payment until the following

investment trust enterprise

proceed to enter into a

of directors.

(a) The purpose, necessity and anticipated benefit of the acquisition or

issued by adomestic securities

(SITE), the Company may not

transaction contract or make a

matters have been approved by

the Audit Committee and board

payment until the following

investment trust enterprise

proceed to enter into a

Subparagraph 5 is added:

1) For the purpose of enhancing management on related party transaction and protecting minority shareholders' rights to express opinion over transaction between the Company and related party while preventing the Company from conducting transactions with major stakeholders through subsidiaries of non-domestically listed companies, it is hereby stipulated,

of directors.

Before amendment	After amendment	Reason for amendment
(b) The reason for choosing the	(b) The reason for choosing the	under references of
related party as a trading	related party as a trading	international major
counterparty.	counterparty.	capital markets'
(c) With respect to the	(c) With respect to the	regulations requiring
acquisition of real property	acquisition of real property	that transactions with
or right-of-use assetsfrom a	or right-of-use assetsfrom a	major stakeholders
related party, information	related party, information	shall be first approved
regarding appraisal of the	regarding appraisal of the	by Annual General
reasonableness of the	reasonableness of the	Meeting, that, for
preliminary transaction	preliminary transaction	asset acquisition or
terms in accordance with	terms in accordance with	disposal transactions
Article 15 and Article 16.	Article 15 and Article 16.	prescribed in
(d) The date and price at which	(d) The date and price at which	subparagraph (1)
the related party originally	the related party originally	between the Company
acquired thereal property,	acquired thereal property,	or subsidiaries of the
the original trading	the original trading	Company's non-
counterparty, and that	counterparty, and that	domestically listed
trading counterparty's	trading counterparty's	companies and
relationship to the Company	relationship to the Company	stakeholders with
and the related party.	and the related party.	transaction amount
(e) Monthly cash flow forecasts	(e) Monthly cash flow forecasts	reaching more than
for the year commencing	for the year commencing	10% of the
from the anticipated month	from the anticipated month	Company's total
of signing of the contract,	of signing of the contract,	assets, the Company shall first submit
and evaluation of the	and evaluation of the	related materials to
necessity of the transaction,	necessity of the transaction,	Annual General
and reasonableness of the	and reasonableness of the	Meeting for approval
funds utilization.	funds utilization.	before conducting
(f) An appraisal report from a	(f) An appraisal report from a	such transactions. The
professional appraiser or a	professional appraiser or a	Company shall be
CPA's opinion obtained in	CPA's opinion obtained in	responsible for
compliance with the	compliance with the	implementing
preceding article.	preceding article.	requirements on
(g) Restrictive covenants and	(g) Restrictive covenants and	matters to be
other important stipulations	other important stipulations	submitted to Annual
associated with the	associated with the	General Meeting for
transaction.	transaction.	approval by
(2) The calculation of the	(2) With respect to the types of	subsidiaries of non-
transaction amounts referred to	transactions listed below, when	domestically listed
in the preceding paragraph shall	to be conducted between the	companies.
be made in accordance with	Company and its subsidiaries,	(2) Under considerations
Article 11.1.(2) herein, and	or between its subsidiaries in	of the needs for
		•

Before amendment
"within the preceding year" as
used herein refers to the year
preceding the date of
occurrence of the current
transaction. Items that have
been approved by the Audit
Committee and board of
directors need not be counted
toward the transaction amount

- (3) With respect to the types of transactions listed below, when to be conducted between the Company and its subsidiaries, or between its subsidiaries in which it directly or indirectly holds 100 percent of the issued shares or authorized capital, the Company's board of directors may pursuant to Article 4.2 and 4.3 delegate the board chairman to decide such matters when the transaction is within a certain amount and have the decisions subsequently submitted to and ratified by the next board of directors meeting:
 - (a) Acquisition or disposal of equipment or right-of-use assets thereof held for business use.
 - (b) Acquisition or disposal of real property right-of-use assets held for business use.
- (4) When a matter is submitted for discussion by the board of directors pursuant to paragraph 1, the board of directors shall take into full consideration each independent director's opinions. If an independent director objects to or expresses reservations about any matter, it shall be recorded in the

After amendment

which it directly or indirectly holds 100 percent of the issued shares or authorized capital, the Company's board of directors may pursuant to Article 4.2 and 4.3 delegate the board chairman to decide such matters when the transaction is within a certain amount and have the decisions subsequently submitted to and ratified by the next board of directors meeting:

- (a) Acquisition or disposal of equipment or right-of-use assets thereof held for business use.
- (b) Acquisition or disposal of real property right-of-use assets held for business use.
- (3) When a matter is submitted for discussion by the board of directors pursuant to paragraph 1, the board of directors shall take into full consideration each independent director's opinions. If an independent director objects to or expresses reservations about any matter, it shall be recorded in the minutes of the board of directors meeting.
- (4) The matters for which paragraph 1 requires review by the Audit Committee shall first be approved by more than half of all Audit Committee members and then submitted to the board of directors for a resolution, and shall be subject to mutatis mutandis application of Article 14.4 and 14.5.
- (5) In the event that the Company or a subsidiary of non-

comprehensive business planning between the Company and subsidiary or between subsidiaries as well as references of exemption regulations from aforementioned international major capital markets, it is hereby prescribed in proviso that transactions between these companies are exempted from being submitted to Annual General Meeting for

resolution.

Reason for amendment

(3) In the event that aforementioned major stakeholder transaction belongs to situations prescribed in Subparagraph 1 to Subparagraph 3, Paragraph 1, Article 185 of Company Act, resolution from Annual General Meeting shall be conducted in accordance with special resolution requirements prescribed in Article 185 of Company Act as well as aforementioned matters and related regulations in Company Act.

Original subparagraph 2 of

Before amendment	After amendment	Reason for amendment
Before amendment minutes of the board of directors meeting. (5) The matters for which paragraph 1 requires review by the Audit Committee shall first be approved by more than half of all Audit Committee members and then submitted to the board of directors for a resolution, and shall be subject to mutatis mutandis application of Article 14.4 and 14.5. 3. Omitted. 4. Omitted.	domestically listed company is engaged in transaction prescribed in subparagraph 1 and transaction amount reaching more than 10% of the Company's total assets, the Company can only enter transaction agreement and proceed with payments after materials prescribed in	paragraph 2 is now moved to subparagraph 6. With the addition of subparagraph 5, subparagraph 6 is hereby amended to include calculation of transaction amount into transactions to be submitted to Annual General Meeting for approval.
	in accordance with the processing procedures hereto. 3. Omitted.	
1 7	4. Omitted.	4 4 4
Article 11	Article 11	1. Amendment was made
Public Announcement Procedures:	Public Announcement Procedures:	in accordance with the
1. Matters for the Company's Public	1. Matters for the Company's Public	revision of
Announcement:	Announcement:	"Regulations
(1) Under any of the following	(1) Under any of the following	Governing with

Before amendment	After amendment	Reason for amendment
circumstances, the Company	circumstances, the Company	Acquisition and
acquiring or disposing of assets	acquiring or disposing of assets	Disposal of Assets by
shall publicly announce and	shall publicly announce and	Public Companies".
report the relevant information	report the relevant information	2. Amendment was made
on the FSC's designated	on the FSC's designated	in accordance with
website in the appropriate	website in the appropriate	current listed
format as prescribed by	format as prescribed by	company's exemption
regulations within 2 days	regulations within 2 days	of announcement and
commencing immediately from	commencing immediately from	report on transactions
the date of occurrence of the	the date of occurrence of the	of domestic
event:	event:	government bonds.
(a) Acquisition or disposal of	(a) Acquisition or disposal of	Item 5-1, Subparagraph
real property or right-of-use	real property or right-of-use	1 of paragraph 1 is
assets from or to a related	assets from or to a related	hereby amended
party, or acquisition or	party, or acquisition or	accordingly.
disposal of assets other than	disposal of assets other than	Announcement and
real property or right-of-use	real property or right-of-use	report on transactions
assets from or to a related	assets from or to a related	of international
party where the transaction	party where the transaction	government bonds with
amount reaches 20 percent	amount reaches 20 percent	credit ratings not lower
or more of paid-in capital,	or more of paid-in capital,	than the domestic
10 percent or more of the	10 percent or more of the	government bond is
Company's total assets, or	Company's total assets, or	also exempted.
NT\$300 million or more;	NT\$300 million or more;	
provided, this shall not	provided, this shall not	
apply to trading of domestic	apply to trading of domestic	
government bonds or bonds	government bonds or bonds	
under repurchase and resale	under repurchase and resale	
agreements, or subscription	agreements, or subscription	
or redemption of domestic	or redemption of domestic	
money market funds issued	money market funds issued	
by a domestic securities	by a domestic securities	
investment trust enterprise	investment trust enterprise	
(SITE).	(SITE).	
(b) Merger, demerger,	(b) Merger, demerger,	
acquisition, or transfer of	acquisition, or transfer of	
shares.	shares.	
(c) Where the type of asset	(c) Where the type of asset	
acquired or disposed is	acquired or disposed is	
equipment/machinery or	equipment/machinery or	
right-of-use assets for	right-of-use assets for	
business use, the trading	business use, the trading	
counterparty is not a related	counterparty is not a related	

Before amendment	After amendment	Reason for amendment
party, and the transaction	party, and the transaction	
amount is less than NT\$500	amount is less than NT\$500	
million.	million.	
(d) Acquisition or disposal by a	(d) Acquisition or disposal by a	
public company in the	public company in the	
construction business of real	construction business of real	
property or right-of-use	property or right-of-use	
assets thereof for	assets thereof for	
construction use, and	construction use, and	
furthermore the transaction	furthermore the transaction	
counterparty is not	counterparty is not	
a related party, and the	a related party, and the	
transaction amount reaches	transaction amount reaches	
NT\$500 million.	NT\$500 million.	
(e) Where an asset transaction	(e) Where an asset transaction	
other than any of those	other than any of those	
referred to in the preceding	referred to in the preceding	
four subparagraphs, a	four subparagraphs, a	
disposal of receivables by a	disposal of receivables by a	
financial institution, or an	financial institution, or an	
investment in the mainland	investment in the mainland	
China area reaches 20	China area reaches 20	
percent or more of paid-in	percent or more of paid-in	
capital or NT\$300 million;	capital or NT\$300 million;	
provided, this shall not	provided, this shall not	
apply to the following	apply to the following	
circumstances:	circumstances:	
(i) Trading of domestic	(i) Trading of domestic	
government bonds.	government bonds or	
(ii) Trading of bonds under	international government	
repurchase/resale	bonds which credit rating is	
agreements, or subscription	not lower than domestic	
or redemption of domestic	government bonds.	
money market fundsissued	(ii) Trading of bonds under	
by a domestic securities	repurchase/resale	
investment trust enterprise	agreements, or subscription	
(SITE).	or redemption of domestic	
(2) The amount of transactions	money market fundsissued	
above shall be calculated as	by a domestic securities	
follows:	investment trust enterprise	
(a) The amount of any	(SITE).	
individual transaction.	(2) The amount of transactions	

Before amendment	After amendment	Reason for amendment
(b) The cumulative transaction	above shall be calculated as	
amount of acquisitions and	follows:	
disposals of the same type of	(a) The amount of any	
underlying asset with the	individual transaction.	
same trading counterparty	(b) The cumulative transaction	
within the preceding year.	amount of acquisitions and	
(c) The cumulative transaction	disposals of the same type of	
amount of real property	underlying asset with the	
acquisitions and disposals	same trading counterparty	
(cumulative acquisitions and	within the preceding year.	
disposals, respectively)	(c) The cumulative transaction	
within the same	amount of real property	
development project within	acquisitions and disposals	
the preceding year.	(cumulative acquisitions and	
(d) The cumulative transaction	disposals, respectively)	
amount of acquisitions and	within the same	
disposals (cumulative	development project within	
acquisitions and disposals,	the preceding year.	
respectively) of the same	(d) The cumulative transaction	
security within the	amount of acquisitions and	
preceding year.	disposals (cumulative	
(3) "Within the preceding year" as	acquisitions and disposals,	
used in the preceding paragraph	respectively) of the same	
refers to the year preceding the	security within the	
date of occurrence of the	preceding year.	
current transaction. Items duly	(3) "Within the preceding year" as	
announced in accordance with	used in the preceding paragraph	
these Procedures need not be	refers to the year preceding the	
counted toward the transaction	date of occurrence of the	
amount.	current transaction. Items duly	
2. Omitted.	announced in accordance with	
3. Omitted.	these Procedures need not be	
4. Omitted.	counted toward the transaction	
5. Omitted.	amount.	
	2. Omitted.	
	3. Omitted.	
	4. Omitted.	
	5. Omitted.	

Before amendment	After amendment	Reason for amendment
Article 15	Article 15	Adding the date of the latest
Supplements:	Supplements:	amendment.
Matters not prescribed in these	Matters not prescribed in these	
Procedures hereto shall be processed in	Procedures hereto shall be processed in	
accordance with related laws and the	accordance with related laws and the	
Company's related rules and	Company's related rules and	
requirements.	requirements.	
These Procedures were enacted on	These Procedures were enacted on	
May 22, 1998.	May 22, 1998.	
The 1st amendment was made on	The 1st amendment was made on	
March 24, 2000.	March 24, 2000.	
The 2nd amendment was made on May	The 2nd amendment was made on May	
13, 2002.	13, 2002.	
The 3rd amendment was made on May	The 3rd amendment was made on May	
19, 2003.	19, 2003.	
The 4th amendment was made on June	The 4th amendment was made on June	
21, 2007.	21, 2007.	
The 5th amendment was made on June	The 5th amendment was made on June	
22, 2012.	22, 2012.	
The 6th amendment was made on June	The 6th amendment was made on June	
24, 2014.	24, 2014.	
The 7th amendment was made on June	The 7th amendment was made on June	
16, 2017.	16, 2017.	
The 8th amendment was made on June	The 8th amendment was made on June	
25, 2019.	25, 2019.	
	The 9th amendment was made on May	
	26, 2022.	